Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 52
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Food biodiversity and mortality in older Mediterranean adults with high cardiovascular risk

  • Shyam, Sangeetha
  • Babio, Nancy
  • Paz-Graniel, Indira
  • Martínez-González, Miguel Ángel, 1957-
  • Sorlí, José Vicente
  • Estruch, Ramón
  • Ros, Emilio
  • Tojal Sierra, Lucas
  • Gómez-Gracia, Enrique
  • Fiol, Miquel
  • Lapetra, José
  • Serra Majem, Lluís
  • Riera-Mestre, Antoni
  • Toledo, Estefania
  • Ramirez-Sabio, Judith B
  • Castañer, Olga
  • Lamuela Raventós, Rosa Ma.
  • Margara Escudero, Hernando J.
  • Fitó Colomer, Montserrat
  • Salas Salvadó, Jordi
The food system is a key determinant of population and planetary health. As the "one planet, one health" approach gains momentum, evaluating "food biodiversity" and its association with mortality in high-risks populations is increasingly important. Hence, we evaluated the associations of food biodiversity with all-cause and cause-specific mortality in a Spanish cohort of older adults at high cardiovascular risks. Food biodiversity was defined using dietary species richness (DSR), the count of unique plants and animal species consumed by an individual. DSR was cumulatively calculated over the PREDIMED study follow-up, using yearly food frequency questionnaire data. The association of food biodiversity with all-cause and cause-specific mortality was assessed using Cox regression, while controlling for confounders. We analyzed data from 7210 participants (58 % women), with a median age of 67 years. DSR in the cohort ranged between 16 and 57 (median: 48). Over a median follow-up of 6 years, 425 deaths were recorded (103 deaths from cardiovascular diseases (CVD), 169 cancer deaths, and 153 deaths due to other-causes). DSR was only moderately correlated with adherence to the Mediterranean diet. On average, when fully adjusted, every additional species over the follow-up period was associated with a Hazard Ratio (HR (95 % Confidence Interval) of 0.91(0.90,0.93) for all-cause mortality, 0.93(0.90,0.96) for CVD mortality, 0.92 (0.89,0.94) for cancer deaths, and a 0.91(0.89,0.94) for deaths from other causes. Dietary recommendations to improve food biodiversity may increase longevity., Supported by Instituto de Salud Carlos III, Spanish Ministry of Health, through grants provided to research networks specifically developed for the study (RTIC G03/140, to Dr. Estruch, and RTIC RD 06/0045, to Dr. Martínez-González); Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición; and grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, and P11/02505), Ministerio de Ciencia e Innovación (AGL-2009-13906-C02 and AGL2010-22319-C03), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVACOMP2010-181, GVACOMP2011-151, CS2010-AP-111, and CS2011-AP-042), and Regional Government of Navarra (P27/2011).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The PREDIMED trial, Mediterranean diet and health outcomes: How strong is the evidence?

  • Guasch-Ferré, Marta
  • Salas-Salvadó, Jordi
  • Ros, Emilio
  • Estruch, Ramón
  • Corella, Dolores
  • Fitó Colomer, Montserrat
  • Martínez-González, Miguel Ángel, 1957-
  • PREDIMED investigators
AIMS: To address potential controversies on the health benefits of the Mediterranean diet (MedDiet) after PREDIMED, a randomized trial of MedDiet for primary cardiovascular prevention. We have focused on: a) the PREDIMED study design, b) analysis of PREDIMED data and c) interpretation of its results. DATA SYNTHESIS: Regarding the design of the trial, its early termination and between-group differences in the intensity of the intervention are potential causes of concern. The planned duration was 6 years but the trial was prematurely stopped when an interim analysis at 4.8-year provided sufficient evidence of benefit for the two MedDiets. In the MedDiet groups supplemented with extra-virgin olive oil or mixed-nuts, the primary composite endpoint (myocardial infarction, stroke, or cardiovascular death) was reduced by 30% and 28% respectively, as compared with the control group. Final results did not change after taking into account the different intensity of educational efforts during the trial. Other potential doubts related to data analysis (e.g., intention to treat versus a per-protocol approach, and consequences of dropouts) should not be causes of concern. Finally, we addressed alternative interpretations of the effect on all-cause mortality. The protocol-defined primary endpoint was a composite cardiovascular endpoint, not all-cause mortality. To analyze total mortality, we would have needed a much larger sample size and longer follow-up. Therefore, the PREDIMED results cannot be used to draw firm conclusions on MedDiets and all-cause mortality. CONCLUSIONS: The PREDIMED study was designed to overcome three major problems of previous nutritional research: a) residual confounding, addressed by using a randomized design; b) single-nutrient approaches, by randomizing an overall dietary pattern; and c) the limitations of assessing only intermediate risk markers, by using hard clinical end-points., Supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research net-works specifically developed for the trial (RTIC G03/140(2003e2005), to Dr. Estruch; RTIC RD 06/0045(2006e2013), to Dr. Martínez González and through Centrode Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBERobn]), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC06/2007), Fondo de Investigación Sanitaria de Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100,PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407,PI10/02658, PI11/01647, and P11/02505), Ministerio de Ciencia e Innovación (AGL-2009-1390 6-C02 and AGL2010-22319-C03), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Divisionof the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109,GVACOMP2010-181, GVACOMP2011-151, CS2010-AP-111 and CS2011 AP-042), and Regional Government of Navarra(P27/2011). Dr. Estruch reports serving on the board of and receiving lecture fees from the Research Foundationon Wine and Nutrition (FIVIN); serving on the boards of the Beer and Health Foundation and the European Foun-dation for Alcohol Research (ERAB); receiving lecture fees from Cerveceros de España and Sanofi Aventis; andreceiving grant support through his institution fromNovartis. Dr. Ros reports serving on the board of andreceiving travel support, as well as grant support throughhis institution, from the California Walnut Commission; serving on the board of the Flora Foundation (Unilever);serving on the board of and receiving lecture fees from Roche; serving on the board of and receiving grant support through his institution from Amgen; receiving consulting fees from Damm and Abbott Laboratories; receiving consulting fees and lecture fees, as well as grant support through his institution, from Merck; receiving lecture fees from Danone, Pace, AstraZeneca, and Rottapharm; receiving lecture fees and payment for the development of educational presentations, as well as grant support through his institution, from Ferrer; receiving payment for the devel-opment of educational presentations from Recordati; and receiving grant support through his institution from Sanofi-Aventis, Takeda, Daiichi Sankyo, Nutrexpa, Feiraco, Unilever,and Karo Bio. Dr. Salas-Salvadó reports serving on the boardof and receiving grant support through his institution fromthe International Nut and Dried Fruit Council; receiving consulting fees from Danone; and receiving grant support through his institution from Eroski and Nestlé. No other potential conflict of interest relevant to this article was reported.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Low serum iron levels and risk of cardiovascular disease in high risk elderly population: Nested case-control study in the PREvención con DIeta MEDiterránea (PREDIMED) trial

  • Gutierrez Bedmar, Mario
  • Olmedo, Pablo
  • Gil, Fernando
  • Ruiz-Canela, Miguel
  • Martínez-González, Miguel Ángel, 1957-
  • Salas Salvadó, Jordi
  • Babio, Nancy
  • Fitó Colomer, Montserrat
  • Val, José Luis del
  • Corella, Dolores
  • Sorlí, José Vicente
  • Ros, Emilio
  • Fiol, Miquel
  • Estruch, Ramón
  • Lapetra, José
  • Arós, Fernando
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Gómez Gracia, Enrique
Background & aims: Epidemiological data on iron status and cardiovascular disease (CVD) are still controversial. The aim of this study was to determine whether low serum iron (SI) levels are associated with an increased odds of first CVD event in a population at high cardiovascular risk. Methods: Case-control study design nested within the "PREvención con DIeta MEDiterránea" (PREDIMED) trial. A total of 207 participants diagnosed with CVD (myocardial infarction, stroke or cardiovascular death) during follow-up period (2003-2010) were matched by sex, age and intervention group to 436 controls by incidence density sampling. Median time between serum sample collection and subsequent CVD event occurrence was 0.94 years. Inductively coupled plasma mass spectrometry analysis was used to determine SI levels. In-person interviews, medical record reviews, and validated questionnaires were used to assess covariates. Multivariable-adjusted odds ratios (ORs) of CVD were calculated with conditional logistic regression. Results: Mean SI levels were higher in men than in women (1224.0 μg/L vs. 1093.8 μg/L; p < 0.001). Among women, but not in men, the mean SI concentration was lower in cases than in controls (1008.5 μg/L vs. 1132.9 μg/L; p = 0.030). There was a gradual decrease in the multivariable-adjusted ORs of CVD with increasing SI levels (highest vs. lowest quartile: OR = 0.55, 95% CI: 0.32-0.93; ptrend = 0.020). This inverse relationship was more pronounced among women (highest vs. lowest quartile: OR = 0.15, 95% CI: 0.03-0.69; ptrend = 0.011). Conclusions: The present findings are consistent with previously reported inverse associations between SI and CVD. SI levels as an independent marker of short-term cardiovascular risk may be useful for risk assessment in older populations. Trial registration: www.controlled-trials.com; International Standard Randomized Controlled Trial Number (ISRCTN): 35,739,639. Registered 5 October 2005. Retrospectively registered., This research was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140; RTIC RD 06/0045 “PREDIMED”), and JR14/00008, and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (Proyecto de Investigación (PI04-2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462), the Ministerio de Ciencia e Innovación (Recursos y teconologia agroalimentarias (AGL)-2009-13906-C02 and AGL2010-22319-C03 and AGL2013-49083C3-1-R), the Ministerio de Economía y Competitividad-Fondos FEDER-Instituto de Salud Carlos III (UNGR15-CE-3380), the Fundación Mapfre 2010, the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, the Generalitat Valenciana (Generalitat Valenciana Ayuda Complementatia GVACOMP) 06109, GVACOMP2010-181, GVACOMP2011-151), Conselleria de Sanitat y AP; Atención Primaria (CS) 2010-AP-111, and CS2011-AP-042), Regional Government of Navarra (P27/2011), and Centre Català de la Nutrició de l'Institut d'Estudis Catalans. Hojiblanca and Patrimonio Communal Olivarero donated extra-virgin olive oil; the California Walnut Commission donated walnuts; Borges donated almonds; La Morella Nuts donated hazelnuts. ROLE OF THE FUNDERS: funding sources had no role in the designing and conducting of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Circulating amino acids and risk of peripheral artery disease in the PREDIMED Trial

  • Razquin, Cristina
  • Fitó Colomer, Montserrat
  • Martínez-González, Miguel Ángel, 1957-
Effective prevention and risk prediction are important for peripheral artery disease (PAD) due to its poor prognosis and the huge disease burden it produces. Circulating amino acids (AA) and their metabolites may serve as biomarkers of PAD risk, but they have been scarcely investigated. The objective was to prospectively analyze the associations of baseline levels of plasma AA (and their pathways) with subsequent risk of PAD and the potential effect modification by a nutritional intervention with the Mediterranean diet (MedDiet). A matched case-control study was nested in the PREDIMED trial, in which participants were randomized to three arms: MedDiet with tree nut supplementation group, MedDiet with extra-virgin olive oil (EVOO) supplementation group or control group (low-fat diet). One hundred and sixty-seven PAD cases were matched with 250 controls. Plasma AA was measured with liquid chromatography/mass spectrometry at the Broad Institute. Baseline tryptophan, serine and threonine were inversely associated with PAD (ORfor 1 SD increase = 0.78 (0.61–0.99); 0.67 (0.51–0.86) and 0.75 (0.59–0.95), respectively) in a multivariable-adjusted conditional logistic regression model. The kynurenine/tryptophan ratio was directly associated with PAD (ORfor 1 SD increase = 1.50 (1.14–1.98)). The nutritional intervention with the MedDiet+nuts modified the association between threonine and PAD (p-value interaction = 0.018) compared with the control group. However, subjects allocated to the MedDiet+EVOO group were protected against PAD independently of baseline threonine. Plasma tryptophan, kynurenine/tryptophan ratio, serine and threonine might serve as early biomarkers of future PAD in subjects at a high risk of cardiovascular disease. The MedDiet supplemented with EVOO exerted a protective effect, regardless of baseline levels of threonine., This work was supported by the National Institutes of Health research grant R01HL118264 (1R01HL118264-01/2R01HL118264-05/2R01HL118264-09). The PREDIMED trial was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140 to Ramón Estruch during 2003–2005; RTIC RD 06/0045 to Miguel A. Martínez-González during 2006–2013 and through the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBEROBN]), and by grants from the Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04–2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462 and JR17/00022), the Ministerio de Ciencia e Innovación (AGL-2009–13906-C02, AGL2010–22319-C03 and SAF2016–80532-R), the Fundación Mapfre 2010 (no role in the design, implementation, analysis or interpretation of the data), the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVA-COMP2010–181, GVACOMP2011–151, CS2010-AP-111, PROMETEO 17/2017 and CS2011-AP-042), the Fundació La Marató-TV3 (grants 294/C/2015 and 538/U/2016 (no role in the design, implementation, analysis or interpretation of the data)) and the Regional Government of Navarra (P27/2011). Marta Guasch-Ferré was supported by the American Diabetes Association, grant #1-18-PMF-029. Jordi Salas-Salvadó was partially supported by ICREA under the ICREA Academia programme. Wittenbecher was supported by the SciLifeLab & Wallenberg Data Driven Life Science Program (grant: KAW 2020.0239). Marta Guasch-Ferré was supported by NNF18CC0034900.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Metabolites related to purine catabolism and risk of type 2 diabetes incidence; modifying effects of the TCF7L2-rs7903146 polymorphism

  • Papandreou, Christopher
  • Li, Jun
  • Liang, Liming
  • Bulló, Mònica
  • Zheng, Yan
  • Ruiz-Canela, Miguel
  • Yu, Edward
  • Guasch-Ferré, Marta
  • Razquin, Cristina
  • Clish, Clary B.
  • Corella, Dolores
  • Estruch, Ramón
  • Ros, Emilio
  • Fitó Colomer, Montserrat
  • Arós, Fernando
  • Serra-Majem, Luis
  • Rosique-Esteban, Nuria
  • Martínez-González, Miguel Ángel, 1957-
  • Hu, Frank B.
  • Salas-Salvadó, Jordi
Studies examining associations between purine metabolites and type 2 diabetes (T2D) are limited. We prospectively examined associations between plasma levels of purine metabolites with T2D risk and the modifying effects of transcription factor-7-like-2 (TCF7L2) rs7903146 polymorphism on these associations. This is a case-cohort design study within the PREDIMED study, with 251 incident T2D cases and a random sample of 694 participants (641 non-cases and 53 overlapping cases) without T2D at baseline (median follow-up: 3.8 years). Metabolites were semi-quantitatively profiled with LC-MS/MS. Cox regression analysis revealed that high plasma allantoin levels, including allantoin-to-uric acid ratio and high xanthine-to-hypoxanthine ratio were inversely and positively associated with T2D risk, respectively, independently of classical risk factors. Elevated plasma xanthine and inosine levels were associated with a higher T2D risk in homozygous carriers of the TCF7L2-rs7903146 T-allele. The potential mechanisms linking the aforementioned purine metabolites and T2D risk must be also further investigated., This study was supported by research grant R01-DK-102896 from the National Institutes of Health. The Prevención con DietaMediterránea (PREDIMED) trial was supported by the official funding agency for biomedical research of the Spanish government, the Instituto de Salud Carlos III, through grants provided to research networks specifically developed for the trial [grant RTIC G03/140 (to Ramón Estruch); grant RTIC RD 06/0045 (to Miguel A. Martínez-González)] and through the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición and by grants from Centro Nacional de Investigaciones Cardiovasculares (grant CNIC 06/2007), the Fondo de Investigación Sanitaria Fondo Europeo de Desarrollo Regional (grants PI04–2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, and PI13/00462), the Ministerio de Ciencia e Innovación (grants AGL-2009–13906-C02 and AGL2010–22319-C03), the Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (grant PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (grants ACOMP06109, GVA-COMP2010–181, GVACOMP2011–151, CS2010-AP-111, and CS2011-AP-042), and the Regional Government of Navarra (grant P27/2011). Genotyping of the TCF7L2-rs7903146 polymorphism was supported by PROMETEO17/2017 from the Generalitat Valenciana, and 538/U/2016 from Fundacio la Marato-TV3. Dr. Christopher Papandreou was supported by a postdoctoral fellowship granted by the Autonomous Government of Catalonia (PERIS 2016-2020 INCORPORACIÓ DE CIENTÍFICAS I TECNÒLEGS, SLT002/0016/00428). Dr Marta Guasch-Ferré was supported by a postdoctoral fellowship granted by the Lilly Foundation European Association of Diabetes (EASD) through the Institut d’Investigacions Sanitàries Pere i Virgili (IISPV), Tarragona, Spain. The authors are indebted to George A. Fragkiadakis (Department of Nutrition & Dietetics, Technological Education Institute of Crete, Greece) for his intellectual contributions to this manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Plasma lipidome and risk of atrial fibrillation: results from the PREDIMED trial

  • Toledo, Estefania
  • Fitó Colomer, Montserrat
  • Martínez-González, Miguel Ángel, 1957-
The potential role of the lipidome in atrial fibrillation (AF) development is still widely unknown. We aimed to assess the association between lipidome profiles of the Prevención con Dieta Mediterránea (PREDIMED) trial participants and incidence of AF. We conducted a nested case-control study (512 incident centrally adjudicated AF cases and 735 controls matched by age, sex, and center). Baseline plasma lipids were profiled using a Nexera X2 U-HPLC system coupled to an Exactive Plus orbitrap mass spectrometer. We estimated the association between 216 individual lipids and AF using multivariable conditional logistic regression and adjusted the p values for multiple testing. We also examined the joint association of lipid clusters with AF incidence. Hitherto, we estimated the lipidomics network, used machine learning to select important network-clusters and AF-predictive lipid patterns, and summarized the joint association of these lipid patterns weighted scores. Finally, we addressed the possible interaction by the randomized dietary intervention.Forty-one individual lipids were associated with AF at the nominal level (p < 0.05), but no longer after adjustment for multiple-testing. However, the network-based score identified with a robust data-driven lipid network showed a multivariable-adjusted ORper+1SD of 1.32 (95% confidence interval: 1.16-1.51; p < 0.001). The score included PC plasmalogens and PE plasmalogens, palmitoyl-EA, cholesterol, CE 16:0, PC 36:4;O, and TG 53:3. No interaction with the dietary intervention was found. A multilipid score, primarily made up of plasmalogens, was associated with an increased risk of AF. Future studies are needed to get further insights into the lipidome role on AF.Current Controlled Trials number, ISRCTN35739639., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This study was supported by the National Institutes of Health grants R01HL118264 and R01DK102896. The PREDIMED trial (Prevención con Dieta Mediterránea) was supported by the official funding agency for biomedical research of the Spanish government, the Instituto de Salud Carlos III, through the grant coordinated by MAMG for a research network specifically developed during 2006-2013 for the trial (RTIC RD 06/0045) and a previous grant coordinated by RE (RTIC G03/140) during 2003-2005 and through the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición and by grants from: the Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007); the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04–2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, and PI13/00462); the Ministerio de Ciencia e Investigación (AGL-2009–13906-C02 and AGL2010–22319-C03); the Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007); the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVA-COMP2010–181, GVACOMP2011–151, CS2010-AP-111, and CS2011-AP-042); the Regional Government of Navarra (P27/2011); and the European Union in the frame of the Joint Programming Initiative ‘A Healthy Diet for a Healthy Life’ to the Fatty Acid Metabolism—Interlinking Diet with Cardiometabolic Health (FAME)-consortium (01EA1704). J. Salas-Salvadó, gratefully acknowledges the financial support by ICREA under the ICREA Academia programme. C. Wittenbecher was supported by an individual fellowship from the German Research Foundation (DFG).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Arginine catabolism metabolites and atrial fibrillation or heart failure risk: 2 case-control studies within the Prevención con Dieta Mediterránea (PREDIMED) trial

  • Goni, Leticia
  • Fitó Colomer, Montserrat
  • Ruiz-Canela, Miguel
Background Arginine-derived metabolites are involved in oxidative and inflammatory processes related to endothelial functions and cardiovascular risks. Objectives We prospectively examined the associations of arginine catabolism metabolites with the risks of atrial fibrillation (AF) or heart failure (HF), and evaluated the potential modifications of these associations through Mediterranean diet (MedDiet) interventions in a large, primary-prevention trial. Methods Two nested, matched, case-control studies were designed within the Prevención con Dieta Mediterránea (PREDIMED) trial. We selected 509 incident cases and 547 matched controls for the AF case-control study and 326 cases and 402 matched controls for the HF case-control study using incidence density sampling. Fasting blood samples were collected at baseline and arginine catabolism metabolites were measured using LC-tandem MS. Multivariable conditional logistic regression models were applied to test the associations between the metabolites and incident AF or HF. Interactions between metabolites and intervention groups (MedDiet groups compared with control group) were analyzed with the likelihood ratio test. Results Inverse association with incident AF was observed for arginine (OR per 1 SD, 0.83; 95% CI: 0.73–0.94), whereas a positive association was found for N1-acetylspermidine (OR for Q4 compared with Q1 1.58; 95% CI: 1.13–2.25). For HF, inverse associations were found for arginine (OR per 1 SD, 0.82; 95% CI: 0.69–0.97) and homoarginine (OR per 1 SD, 0.81; 95% CI: 0.68–0.96), and positive associations were found for the asymmetric dimethylarginine (ADMA) and symmetric dimethlyarginine (SDMA) ratio (OR per 1 SD, 1.19; 95% CI: 1.02–1.41), N1-acetylspermidine (OR per 1 SD, 1.34; 95% CI: 1.12–1.60), and diacetylspermine (OR per 1 SD, 1.20; 95% CI: 1.02–1.41). In the stratified analysis according to the dietary intervention, the lower HF risk associated with arginine was restricted to participants in the MedDiet groups (P-interaction = 0.044). Conclusions Our results suggest that arginine catabolism metabolites could be involved in AF and HF. Interventions with the MedDiet may contribute to strengthen the inverse association between arginine and the risk of HF. This trial was registered at controlled-trials.com as ISRCTN35739639., Supported by National Heart, Lung, and Blood Institute research grant R01HL118264 (to FBH). The PREDIMED (Prevención con Dieta Mediterránea) trial was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III, through grants provided to research networks specifically developed for the trial: RTIC G03/140 (to RE) during 2003–2005 and RTIC RD 06/0045 (to MAM-G) during 2006–2013 and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (to MAM-G); Centro Nacional de Investigaciones Cardiovasculares grant CNIC 06/2007; Fondo de Investigación Sanitaria—Fondo Europeo de Desarrollo Regional grants PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462, and JR17/00022; Ministerio de Ciencia e Innovación grants AGL-2009-13906- C02, AGL2010-22319-C03, and SAF2016-80532-R; Fundación Mapfre 2010 (which had no role in the design, implementation, analysis, or interpretation of the data); Consejería de Salud de la Junta de Andalucía grant PI0105/2007; Public Health Division of the Department of Health of the Autonomous Government of Catalonia; Generalitat Valenciana grants ACOMP06109, GVA-COMP2010-181, GVACOMP2011-151, CS2010-AP111, PROMETEO 17/2017, and CS2011-AP-042; Fundació La MaratóTV3 (which had no role in the design, implementation, analysis, or interpretation of the data) grants 294/C/2015 and 538/U/2016; and Regional Government of Navarra grant P27/2011.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Egg consumption and cardiovascular disease according to diabetic status: The PREDIMED study

  • Díez-Espino, J.
  • Basterra-Gortari, F. Javier
  • Salas-Salvadó, Jordi
  • Buil-Cosiales, Pilar
  • Corella, Dolores
  • Schröder, Helmut, 1958-
  • Estruch, Ramón
  • Ros, Emilio
  • Gómez-Gracia, Enrique
  • Arós, Fernando
  • Fiol, Miquel
  • Lapetra, José
  • Serra-Majem, Luis
  • Pintó Sala, Xavier
  • Babio, Nancy
  • Quiles, Laura
  • Fitó Colomer, Montserrat
  • Martí, Amelia
  • Toledo, Estefania
  • PREDIMED investigators
BACKGROUND: Eggs are a major source of dietary cholesterol and their consumption has been sometimes discouraged. A relationship between egg consumption and the incidence of cardiovascular disease (CVD) has been suggested to be present exclusively among patients with type2 diabetes. AIMS: To assess the association between egg consumption and CVD in a large Mediterranean cohort where approximately 50% of participants had type 2 diabetes. METHODS: We prospectively followed 7216 participants (55-80 years old) at high cardiovascular risk from the PREDIMED (PREvención con DIeta MEDiterránea) study for a mean of 5.8 years. All participants were initially free of CVD. Yearly repeated measurements of dietary information with a validated 137-item food-frequency questionnaire were used to assess egg consumption and other dietary exposures. The endpoint was the rate of major cardiovascular events (myocardial infarction, stroke or death from cardiovascular causes). RESULTS: A major cardiovascular event occurred in 342 participants. Baseline egg consumption was not significantly associated with cardiovascular events in the total population. Non-diabetic participants who ate on average >4 eggs/week had a hazard ratio (HR) of 0.96 (95% confidence interval, 0.33-2.76) in the fully adjusted multivariable model when compared with non-diabetic participants who reported the lowest egg consumption (<2 eggs/week). Among diabetic participants, the HR was 1.33 (0.72-2.46). There was no evidence of interaction by diabetic status. HRs per 500 eggs of cumulative consumption during follow-up were 0.94 (0.66-1.33) in non-diabetics and 1.18 (0.90-1.55) in diabetics. CONCLUSIONS: Low to moderated egg consumption was not associated with an increased CVD risk in diabetic or non-diabetic individuals at high cardiovascular risk. This trial was registered at controlled-trials.com as ISRCTN35739639., Supported by the official funding agency for biomedical research of the Spanish Government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140, to RE; RTIC RD 06/0045, to Miguel A. Martínez-Gonzalez) and through Centro de Investigaci on Biomedica en Red de Fisiopatología de la Obesidad y Nutrici on (CIBERobn), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), the Fondo de Investigacion Sanitaria eFondo Europeo de Desarrollo Regional (Proyecto de Investigacion (PI) 04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/ 1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462), the Ministerio de Ciencia e Innovacion (Recursos y teconologia agroalimentarias (AGL)-2009-13906-C02 and AGL2010-22319-C03 and AGL2013-49083-C3-1-R), the Fundacion Mapfre 2010, the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, the Generalitat Valenciana (Generalitat Valenciana Ayuda Complementaria (GVACOMP) 06109, GVACOMP2010-181, GVACOMP2011-151), Conselleria de Sanitat y AP; Atencion Primaria (CS) 2010-AP-111, and CS2011-AP-042, and Regional Government of Navarra (P27/2011).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Plasma Metabolites From Choline Pathway and Risk of Cardiovascular Disease in the PREDIMED (Prevention With Mediterranean Diet) Study

  • Guasch-Ferré, Marta
  • Hu, Frank B.
  • Ruiz-Canela, Miguel
  • Bulló, Mònica
  • Toledo, Estefania
  • Wang, Dong D.
  • Corella, Dolores
  • Gómez Gracia, Enrique
  • Fiol, Miquel
  • Estruch, Ramón
  • Lapetra, José
  • Fitó Colomer, Montserrat
  • Arós, Fernando
  • Serra-Majem, Luis
  • Ros, Emilio
  • Dennis, Courtney
  • Liang, Liming
  • Clish, Clary B.
  • Martínez-González, Miguel Ángel, 1957-
  • Salas-Salvadó, Jordi
BACKGROUND: The relationship between plasma concentrations of betaine and choline metabolism and major cardiovascular disease (CVD) end points remains unclear. We have evaluated the association between metabolites from the choline pathway and risk of incident CVD and the potential modifying effect of Mediterranean diet interventions. METHODS AND RESULTS: We designed a case-cohort study nested within the PREDIMED (Prevention With Mediterranean Diet) trial, including 229 incident CVD cases and 751 randomly selected participants at baseline, followed up for 4.8 years. We used liquid chromatography-tandem mass spectrometry to measure, at baseline and at 1 year of follow-up, plasma concentrations of 5 metabolites in the choline pathway: trimethylamine N-oxide, betaine, choline, phosphocholine, and α-glycerophosphocholine. We have calculated a choline metabolite score using a weighted sum of these 5 metabolites. We used weighted Cox regression models to estimate CVD risk. The multivariable hazard ratios (95% confidence intervals) per 1-SD increase in choline and α-glycerophosphocholine metabolites were 1.24 (1.05-1.46) and 1.24 (1.03-1.50), respectively. The baseline betaine/choline ratio was inversely associated with CVD. The baseline choline metabolite score was associated with a 2.21-fold higher risk of CVD across extreme quartiles (95% confidence interval, 1.36-3.59; P<0.001 for trend) and a 2.27-fold higher risk of stroke (95% confidence interval, 1.24-4.16; P<0.001 for trend). Participants in the higher quartiles of the score who were randomly assigned to the control group had a higher risk of CVD compared with participants in the lower quartile and assigned to the Mediterranean diet groups (P=0.05 for interaction). No significant associations were observed for 1-year changes in individual plasma metabolites and CVD. CONCLUSIONS: A metabolite score combining plasma metabolites from the choline pathway was associated with an increased risk of CVD in a Mediterranean population at high cardiovascular risk., This work was supported by NIH research grant HL118264. The PREDIMED trial was supported by the official funding agency for biomedical research of the Spanish Government, Instituto de Salud Carlos III, through grants provided to research networks specifically developed for the trial (RTIC G03/140 to Estruch; RTIC RD 06/0045 to Martínez‐González) and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición; and by grants from Centro Nacional de Investigaciones Cardiovasculares (06/2007), Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04–2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, and PI13/00462), Ministerio de Ciencia e Innovación (AGL‐2009–13906‐C02 and AGL2010–22319‐C03), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVA‐COMP2010–181, GVACOMP2011–151, CS2010‐AP‐111, and CS2011‐AP‐042), and Regional Government of Navarra (P27/2011). Guasch‐Ferré was supported by a postdoctoral fellowship granted by the Agency for Administration of University and Research Grants of the Autonomous Government of Catalonia (2014‐BP‐A 00017).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Association between serum copper levels and risk of cardiovascular disease: A nested case-control study in the PREDIMED trial

  • Muñoz-Bravo, Carlos
  • Olmedo, Pablo
  • Gil, Fernando
  • Ruiz-Canela, Miguel
  • Martínez-González, Miguel Ángel, 1957-
  • Martínez, María Ángeles
  • Babio, Nancy
  • Fitó Colomer, Montserrat
  • Val, José Luis del
  • Corella, Dolores
  • Sorlí, José Vicente
  • Ros, Emilio
  • Fiol, Miquel
  • Estruch, Ramón
  • Santos Lozano, José Manuel
  • Arós, Fernando
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Gómez Gracia, Enrique
  • Gutiérrez Bedmar, Mario
Background and aim: Certain trace elements have been associated with increased cardiovascular risk. The aim of this study was to evaluate the association between serum copper (S-Cu) levels and the risk of a first event of cardiovascular disease (CVD) in a population of older adults with high cardiovascular risk. Methods and results: We conducted a case-control study nested within the PREDIMED trial. During a median follow-up of 4.8 years, a total of 207 incident cases diagnosed with CVD were matched for sex, age, and intervention group with 436 controls. Personal interviews, reviews of medical records, and validated questionnaires were used to assess known CVD risk factors. Biological serum samples were collected annually. Inductively coupled plasma mass spectrometry analysis was used to determine S-Cu levels. Adjusted odds ratios were calculated using multivariate conditional logistic regression models. All participants had S-Cu levels within the reference values, 750 μg/L to 1450 μg/L. Among men, but not among women, the mean S-Cu concentration was higher in cases 1014.1 μg/L than in controls 959.3 μg/L; (p = 0.004). In men, the multivariable-adjusted odds ratio for CVD was 2.36 (95% CI 1.07-5.20 for the comparison of the highest vs. the lowest quartile; p for trend = 0.02), in women, it was 0.43 (95% CI 0.11-1.70; p for trend = 0.165). Conclusion: In older Spanish men with high cardiovascular risk, a significant association was observed between high S-Cu levels, but still within the reference values, and an increased risk of a first event of CVD. Our findings suggest a sex difference in CVD risk and S-Cu levels. To confirm this relationship and to analyze the differences observed between men and women, further studies are needed., This research was funded by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140; RTIC RD 06/0045 “PREDIMED”), and JR14/00008, and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC06/2007), the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (Proyecto de Investigación (PI04-2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462), the Ministerio de Ciencia e Innovación (Recursos y teconologia agroalimentarias (AGL)-2009-13906-C02 and AGL2010-22319-C03 and AGL2013-49083C3-1-R), the Ministerio de Economía y Competitividad-Fondos FEDER-Instituto de Salud Carlos III (UNGR15-CE-3380), the Fundación Mapfre 2010, the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, the Generalitat Valenciana (Generalitat Valenciana Ayuda Complementatia GVACOMP) 06109, GVACOMP2010-181, GVACOMP2011-151), Conselleria de Sanitat y AP; Atención Primaria (CS) 2010-AP-111, and CS2011-AP-042), Regional Government of Navarra (P27/2011), and Centre Català de la Nutrició de l'Institut d'Estudis Catalans. Hojiblanca and Patrimonio Communal Olivarero donated extra-virgin olive oil; the California Walnut Commission donated walnuts; Borges donated almonds; La Morella Nuts donated hazelnuts.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Chromium Exposure and Risk of Cardiovascular Disease in High Cardiovascular Risk Subjects - Nested Case-Control Study in the Prevention With Mediterranean Diet (PREDIMED) Study

  • Gutiérrez Bedmar, Mario
  • Martínez-González, Miguel Ángel, 1957-
  • Muñoz-Bravo, Carlos
  • Ruiz-Canela, Miguel
  • Mariscal, Alberto
  • Salas Salvadó, Jordi
  • Estruch, Ramón
  • Corella, Dolores
  • Arós, Fernando
  • Fitó Colomer, Montserrat
  • Lapetra, José
  • Serra-Majem, Luis
  • Ros, Emilio
  • Alonso-Gómez, Ángel
  • Portolés, Olga
  • Fiol, Miquel
  • Bulló, Mònica
  • Castañer, Olga
  • Pinto, Xavier
  • Gómez-Gracia, Enrique
BACKGROUND: Epidemiological data on chromium (Cr) exposure and the risk of cardiovascular disease (CVD) are still limited. Toenail Cr level (TCL) provides a time-integrated measure reflecting long-term Cr exposure. We measured TCL to assess the hypothesis that long-term Cr exposure was inversely associated with incident CVD in a population at high risk for CVD.Methods and Results:The associations between TCL and CVD were evaluated in a case-control study nested within the "PREvención con DIeta MEDiterránea" (PREDIMED) trial. We randomly selected 147 of the 288 patients diagnosed with CVD during follow-up and matched them on age and sex to 271 controls. Instrumental neutron activation analysis was used to assess TCL. In-person interviews, medical record reviews, and validated questionnaires were used to assess covariates. The fully adjusted OR for the highest vs. lowest quartile of toenail Cr was 0.54 (95% CI: 0.26-1.14; Ptrend=0.189) for the nested case-control study. On stratification for diabetes mellitus (DM), OR was 1.37 (95% CI: 0.54-3.46; Ptrend=0.364) for the DM group, and 0.25 (95% CI: 0.08-0.80; Ptrend=0.030) for the non-DM group (P for interaction=0.078). CONCLUSIONS: The present findings, although not statistically significant, are consistent with previously reported inverse associations between TCL and CVD. These results, especially for non-DM patients, increase the limited epidemiological knowledge about the possible protective role of Cr against CVD. (Trial registration: www.controlled-trials.com; ISRCTN35739639.)., This research was supported by the official funding agency for biomedical research of the Spanish Government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140 to R.E.; RTIC RD 06/0045 “PREDIMED” to M.A.M-G.), and JR14/00008 to O.C., and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (Proyecto de Investigación (PI) 04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462), Ministerio de Ciencia e Innovación (Recursos y teconologia agroalimentarias (AGL)-2009-13906-C02 and AGL2010-22319-C03 and AGL2013-49083C3-1-R), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (Generalitat Valenciana Ayuda Complementatia GVACOMP) 06109, GVACOMP2010-181, GVACOMP2011-151), Conselleria de Sanitat y AP; Atención Primaria (CS) 2010-AP-111, and CS2011-AP-042), Regional Government of Navarra (P27/2011), and Centre Català de la Nutrició de l’Institut d’Estudis Catalans. Hojiblanca and Patrimonio Communal Olivarero donated extra-virgin olive oil; the California Walnut Commission donated walnuts; Borges donated almonds; La Morella Nuts donated hazelnuts.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Association between the 2018 WCRF/AICR and the low-risk lifestyle scores with colorectal cancer risk in the Predimed Study

  • Barrubés, Laura
  • Babio, Nancy
  • Hernández-Alonso, Pablo
  • Toledo, Estefania
  • Estruch, Ramón
  • Ros, Emilio
  • Fitó Colomer, Montserrat
  • Alonso-Gómez, Ángel
  • Fiol, Miquel
  • Lapetra, José
  • Serra-Majem, Luis
  • Pintó Sala, Xavier
  • Ruiz-Canela, Miguel
  • Corella, Dolores
  • Castañer, Olga
  • Macías-González, Manuel
  • Salas Salvadó, Jordi
Limited longitudinal studies have been conducted to evaluate colorectal cancer (CRC) incidence based on the updated 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) recommendations or other global lifestyle indices, and none in aged populations at high cardiovascular risk. We aimed to assess the association between CRC incidence and adherence to two emerging lifestyles indices (2018 WCRF/AICR score and another low-risk lifestyle (LRL) score comprising smoking status, alcohol consumption, physical activity, diet, and body mass index) in the Spanish PREvencion con DIeta MEDiterranea (PREDIMED) cohort. We studied 7216 elderly men and women at high cardiovascular risk. The 2018 WCRF/AICR and LRL scores were calculated. Multivariable Cox proportional regression models were fitted to estimate the HRs (hazard ratios) and 95% confidence intervals (CIs) for incident CRC events. During a median interquartile range (IQR) follow-up of 6.0 (4.4-7.3) years, 97 CRC events were considered. A significant linear association was observed between each 1-point increment in the WCRF/AICR score (score range from 0 to 7) and CRC risk (HR (95% CI) = 0.79 (0.63-0.99)). Similarly, each 1-point increment in the LRL score (score range from 0 to 5) was associated with a 22% reduction in CRC risk (0.78 (0.64-0.96)). Adhering to emergent lifestyle scores might substantially reduce CRC incidence in elderly individuals. Further longitudinal studies, which take different lifestyle indexes into account, are warranted in the future., The Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN) is an initiative of the Spanish Instituto de Salud Carlos III (ISCIII) which is funded by FEDER “A way to make Europe”/”Investing in your future” (CB06/03). It is supported by the official funding agency for biomedical research of the Spanish government, ISCIII, through grants provided to research networks specifically developed for the trial (RTIC G03/140 and RD 06/0045) through CIBEROBN, and by grants from the Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04–2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI07/0473, PI10/01407, PI10/02658, PI11/01647, and PI11/02505; PI13/00462), Ministerio de Ciencia e Innovación (AGL-2009–13906-C02 and AGL2010–22319-C03), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (PROMETEO17/2017), and the Navarra Regional Government (27/2011). The Fundación Patrimonio Comunal Olivarero and Hojiblanca SA (Málaga, Spain), California Walnut Commission (Sacramento, CA), Borges SA (Reus, Spain), and Morella Nuts SA (Reus, Spain) donated the olive oil, walnuts, almonds, and hazelnuts, respectively, used in the study. J. Salas-Salvadó, the senior author/gratefully acknowledges the financial support by ICREA under the ICREA Academia program. Dr. P.H.-A. is supported by a postdoctoral fellowship (Juan de la Cierva-Formación, FJCI-2017-32205). L. Barrubés has been awarded a grant by the Spanish Ministry of Education, Culture, and Sports (FPU 16/00165). M.M.-G. was the recipient of the Nicolas Monardes Programme from the “Servicio Andaluz de Salud, Junta de Andalucía”, Spain (RC-0001-2018 and C-0029-2023). None of the funding sources played a role in the design, collection, analysis or interpretation of the data or in the decision to submit the manuscript for publication.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Serum selenium and incident cardiovascular disease in the PREvención con DIeta MEDiterránea (PREDIMED) trial: Nested case-control study

  • Gutiérrez Bedmar, Mario
  • Gil, Fernando
  • Olmedo, Pablo
  • Ruiz-Canela, Miguel
  • Martínez-González, Miguel Ángel, 1957-
  • Salas Salvadó, Jordi
  • Babio, Nancy
  • Fitó Colomer, Montserrat
  • Val, José Luis del
  • Corella, Dolores
  • Sorlí, José Vicente
  • Ros, Emilio
  • Fiol, Miquel
  • Estruch, Ramón
  • Santos-Lozano, José
  • Arós, Fernando
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Gómez-Gracia, Enrique
  • Muñoz-Bravo, Carlos
Background: Selenium is an essential trace mineral with potential interest for cardiovascular disease (CVD) prevention owing to its antioxidant properties. Epidemiological data on selenium status and CVD remain inconsistent. The objective of this study was to ascertain whether low serum selenium (SSe) concentrations are related to an increased risk of a first CVD event in a population at high cardiovascular risk. Methods: We undertook a case-control study nested within the “PREvención con DIeta MEDiterránea” (PREDIMED) trial. A total of 207 participants diagnosed with CVD (myocardial infarction, stroke, or cardiovascular death) during the follow-up period (2003−2010) were matched by sex, age, and intervention group to 436 controls by incidence density sampling. Median time between serum sample collection and subsequent CVD event occurrence was 0.94 years. SSe levels were determined using inductively coupled plasma mass spectrometry analysis. Covariates were assessed through validated questionnaires, in-person interviews, and medical record reviews. Conditional logistic regression was used to calculate multivariable-adjusted odds ratios (ORs). Results: Among women, the mean SSe concentration was lower in cases than in controls (98.5 μg/L vs. 103.8 μg/L; p = 0.016). In controls, SSe levels were directly associated with percentage of total energy intake from proteins and fish intake (p for linear trend < 0.001 and 0.049, respectively), whereas SSe concentrations were inversely associated with age, body mass index, and percentage of total energy intake from carbohydrates (p for linear trend < 0.001, 0.008 and 0.016 respectively). In the total group, we observed an inverse dose−response gradient between SSe levels and risk of CVD in the fully-adjusted model (highest vs. lowest quartile: OR = 0.47, 95% CI: 0.27−0.81; ptrend = 0.003). Conclusions: Among elderly individuals at high cardiovascular risk, high SSe concentrations within population reference values are associated with lower first CVD incidence., This research was funded by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140; RTIC RD 06/0045 “PREDIMED”), and JR14/00008, and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (Proyecto de Investigación (PI04-2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462), the Ministerio de Ciencia e Innovación (Recursos y teconologia agroalimentarias (AGL)-2009-13906-C02 and AGL2010-22319-C03 and AGL2013-49083C3-1-R), the Ministerio de Economía y Competitividad-Fondos FEDER-Instituto de Salud Carlos III (UNGR15-CE-3380), the Fundación Mapfre 2010, the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, the Generalitat Valenciana Ayuda Complementatia GVACOMP 06109, GVACOMP2010-181, GVACOMP2011-151, PROMETEO 21/2021, Conselleria de Sanitat y Atención Primaria CS2010-AP-111, and CS2011-AP-042, Regional Government of Navarra (P27/2011), and Centre Català de la Nutrició de l’Institut d’Estudis Catalans. Hojiblanca and Patrimonio Communal Olivarero donated extra-virgin olive oil; the California Walnut Commission donated walnuts; Borges donated almonds; La Morella Nuts donated hazelnuts.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Association between dietary fibre intake and fruit, vegetable or whole-grain consumption and the risk of CVD: results from the PREvención con DIeta MEDiterránea (PREDIMED) trial

  • Buil-Cosiales, Pilar
  • Fitó Colomer, Montserrat
  • PREDIMED investigators
Prospective studies assessing the association between fibre intake or fibre-rich food consumption and the risk of CVD have often been limited by baseline assessment of diet. Thus far, no study has used yearly repeated measurements of dietary changes during follow-up. Moreover, previous studies included healthy and selected participants who did not represent subjects at high cardiovascular risk. We used yearly repeated measurements of diet to investigate the association between fibre intake and CVD in a Mediterranean cohort of elderly adults at high cardiovascular risk. We followed-up 7216 men (55-80 years) and women (60-80 years) initially free of CVD for up to 7 years in the PREvención con DIeta MEDiterránea study (registered as ISRCTN35739639). A 137-item validated FFQ was repeated yearly to assess diet. The primary end point, confirmed by a blinded ad hoc Event Adjudication Committee, was a composite of cardiovascular death, myocardial infarction and stroke. Time-dependent Cox's regression models were used to estimate the risk of CVD according to baseline dietary exposures and to their yearly updated changes. We found a significant inverse association for fibre (P for trend=0·020) and fruits (P for trend=0·024) in age-sex adjusted models, but the statistical significance was lost in fully adjusted models. However, we found a significant inverse association with CVD incidence for the sum of fruit and vegetable consumption. Participants who consumed in total nine or more servings/d of fruits plus vegetables had a hazard ratio 0·60 (95 % CI 0·40, 0·96) of CVD in comparison with those consuming <5 servings/d., The study was financially supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to G03/140, to RE; RTIC RD 06/0045, to MAM-G) and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (Proyecto de Investigación (PI) 04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/ 0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462), the Ministerio de Ciencia e Innovación (Recursos y teconologia agroalimentarias (AGL)-2009-13906-C02 and AGL2010-22319-C03 and AGL2013-49083-C3-1-R), the Fundación Mapfre 2010, the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, the Generalitat Valenciana (Generalitat Valenciana Ayuda Complementatia (GVACOMP) 06109, GVACOMP2010-181, GVACOMP2011-151), Conselleria de Sanitat y AP; Atención Primaria (CS) 2010-AP-111, and CS2011-AP-042) and Regional Government of Navarra (P27/2011).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Red blood cell eicosapentaenoic acid inversely relates to MRI-assessed carotid plaque lipid core burden in elders at high cardiovascular risk

  • Bargallo, Nuria
  • Gilabert, Rosa
  • Romero-Mamani, Edwin-Saúl
  • Cofán, Montserrat
  • Calder, Philip C.
  • Fitó Colomer, Montserrat
  • Corella, Dolores
  • Salas-Salvadó, Jordi
  • Ruiz-Canela, Miguel
  • Estruch, Ramón
  • Ros, Emilio
  • Sala Vila, Aleix
Supplemental marine omega-3 eicosapentaenoic acid (EPA) has an anti-atherosclerotic effect. Clinical research on EPA supplied by the regular diet and atherosclerosis is scarce. In the framework of the PREvención con DIeta MEDiterránea (PREDIMED) trial, we conducted a cross-sectional study in 161 older individuals at high vascular risk grouped into different stages of carotid atherosclerosis severity, including those without ultrasound-detected atheroma plaque (n = 38), with plaques <2.0 mm thick (n = 65), and with plaques ≥2.0 mm (n = 79). The latter were asked to undergo contrast-enhanced 3T magnetic resonance imaging (MRI) and were subsequently grouped into absence (n = 31) or presence (n = 27) of MRI-detectable plaque lipid, a main feature of unstable atheroma plaques. We determined the red blood cell (RBC) proportion of EPA (a valid marker of long-term EPA intake) at enrolment by gas chromatography. In multivariate models, EPA related inversely to MRI-assessed plaque lipid volume, but not to maximum intima-media thickness of internal carotid artery, plaque burden, or MRI-assessed normalized wall index. The inverse association between EPA and plaque lipid content in patients with advanced atherosclerosis supports the notion that this fatty acid might improve cardiovascular health through stabilization of advanced atheroma plaques., CIBEROBN is an initiative of ISCIII, Spain. This study was funded in part by ISCIII (Spanish Ministry of Economy) through grants RTIC G03/140, RTIC RD 06/0045, Centro Nacional de Investigaciones Cardiovasculares CNIC 06/2007, ISCIII FIS PS09/01292; the Spanish Ministry of Science and Innovation (MICINN): AGL2010-22319-C03-02 and AGL2009-13906-C02-02; Fundació “La Marató de TV3”: 294/C/2015. AS-V holds a Miguel Servet I contract (CP12/03299, Instituto de Salud Carlos III, Spain). The funding sources had no involvement in the study design, data collection, analyses, and interpretation of the data or writing of the manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Quality of dietary fat intake and body weight and obesity in a mediterranean population: secondary analyses within the PREDIMED trial

  • Beulen, Yvette
  • Martínez-González, Miguel Ángel, 1957-
  • van de Rest, Ondine
  • Salas-Salvadó, Jordi
  • Sorlí, José Vicente
  • Gómez-Gracia, Enrique
  • Fiol, Miquel
  • Estruch, Ramón
  • Santos-Lozano, José
  • Schröder, Helmut, 1958-
  • Alonso-Gómez, Ángel
  • Serra-Majem, Luis
  • Pinto, Xavier
  • Ros, Emilio
  • Becerra-Tomás, Nerea
  • González, José I.
  • Fitó Colomer, Montserrat
  • Martínez, José Alfredo
  • Gea, Alfredo
A moderately high-fat Mediterranean diet does not promote weight gain. This study aimed to investigate the association between dietary intake of specific types of fat and obesity and body weight. A prospective cohort study was performed using data of 6942 participants in the PREDIMED trial, with yearly repeated validated food-frequency questionnaires, and anthropometric outcomes (median follow-up: 4.8 years). The effects of replacing dietary fat subtypes for one another, proteins or carbohydrates were estimated using generalized estimating equations substitution models. Replacement of 5% energy from saturated fatty acids (SFA) with monounsaturated fatty acids (MUFA) or polyunsaturated fatty acids (PUFA) resulted in weight changes of -0.38 kg (95% Confidece Iinterval (CI): -0.69, -0.07), and -0.51 kg (95% CI: -0.81, -0.20), respectively. Replacing proteins with MUFA or PUFA decreased the odds of becoming obese. Estimates for the daily substitution of one portion of red meat with white meat, oily fish or white fish showed weight changes up to -0.87 kg. Increasing the intake of unsaturated fatty acids at the expense of SFA, proteins, and carbohydrates showed beneficial effects on body weight and obesity. It may therefore be desirable to encourage high-quality fat diets like the Mediterranean diet instead of restricting total fat intake., The PREDIMED trial (www.predimed.es) was supported by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Health, through grants provided to research networks specifically developed for the trial, namely, RTIC G03/140 (Coordinator: R. Estruch, M.D., Ph.D., during 2003-2005) and RTIC RD 06/0045 (Coordinator: M.A. Martínez-González, M.D., Ph.D., during 2006-2013). We also acknowledge CIBERobn (an Initiative of ISCIII), the grants from Centro Nacional de Investigaciones Cardiovasculares CNIC 06/2007, Fondo de Investigación Sanitaria—Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505), Ministerio de Ciencia e Innovación (AGL-2009-13906-C02, AGL2010-22319-C03), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVACOMP2010-181, GVACOMP2011-151, CS2010-AP-111, CS2011-AP-042, and PROMETEO17/2017), and Regional Government of Navarra (P27/2011).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial

  • Martínez-González, Miguel Ángel, 1957-
  • Hernáez, Álvaro
  • Castañer, Olga
  • Salas Salvadó, Jordi
Background: Several large observational prospective studies have reported a protection by the traditional Mediterranean diet against type 2 diabetes, but none of them used yearly repeated measures of dietary intake. Repeated measurements of dietary intake are able to improve subject classification and to increase the quality of the assessed relationships in nutritional epidemiology. Beyond observational studies, randomized trials provide stronger causal evidence. In the context of a randomized trial of primary cardiovascular prevention, we assessed type 2 diabetes incidence according to yearly repeated measures of compliance with a nutritional intervention based on the traditional Mediterranean diet. Methods: PREDIMED (''PREvención con DIeta MEDiterránea'') was a Spanish trial including 7447 men and women at high cardiovascular risk. We assessed 3541 participants initially free of diabetes and originally randomized to 1 of 3 diets: low-fat diet (n = 1147, control group), Mediterranean diet supplemented with extra virgin olive (n = 1154) or Mediterranean diet supplemented with mixed nuts (n = 1240). As exposure we used actual adherence to Mediterranean diet (cumulative average), yearly assessed with the Mediterranean Diet Adherence Screener (scoring 0 to 14 points), and repeated up to 8 times (baseline and 7 consecutive follow-up years). This score was categorized into four groups: < 8, 8-< 10, 10- < 12, and 12-14 points. The outcome was new-onset type 2 diabetes. Results: Multivariable-adjusted hazard ratios from time-varying Cox models were 0.80 (95% confidence interval, 0.70-0.92) per + 2 points in Mediterranean Diet Adherence Screener (linear trend p = .001), and 0.46 (0.25-0.83) for the highest (12-14 points) versus the lowest (< 8) adherence. This inverse association was maintained after additionally adjusting for the randomized arm. Age- and sex-adjusted analysis of a validated plasma metabolomic signature of the Mediterranean Diet Adherence Screener (constituted of 67 metabolites) in a subset of 889 participants also supported these results. Conclusions: Dietary intervention trials should quantify actual dietary adherence throughout the trial period to enhance the benefits and to assist results interpretation. A rapid dietary assessment tool, yearly repeated as a screener, was able to capture a strong inverse linear relationship between Mediterranean diet and type 2 diabetes. Trial registration ISRCTN35739639., Primary Funding Source Instituto de Salud Carlos III. The PREDIMED trial was supported by Instituto de Salud Carlos III (ISCIII), the official funding agency for biomedical research of the Spanish government, through grants provided to research networks specifically developed for the trial (RTIC G03/140, to Ramón Estruch during 2003–2005; RTIC RD 06/0045, to Miguel A. Martínez-González during 2006–2013 and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBEROBN]), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462, and JR17/00022), Ministerio de Ciencia e Innovación (AGL-2009–13906-C02, AGL2010- 22319-C03, AGL2011-23430, and SAF2016–80532-R), Fundación Mapfre 2010 (no role in the design, implementation, analysis or interpretation of the data), Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (PROMETEO 17/2017, and PROMETEO 21/2021), Fundació La Marató-TV3 (grants 294/C/2015 and 538/U/2016 (no role in the design, implementation, analysis or interpretation of the data)), Agencia Canaria de Investigación, Innovación y Sociedad de la Información-EU FEDER (PI 2007/050 and CS2011-AP-042), and Regional Government of Navarra (P27/2011). The metabolomic study was supported by research grant NIDDK-R01DK 102896 from the National Institutes of Health. Donations of olive oil, walnuts, almonds, and hazelnuts were made respectively by the Fundación Patrimonio Comunal Olivarero and Hojiblanca (Malaga, Spain), California Walnut Commission (Sacramento, California), Borges (Reus, Spain), and Morella Nuts (Reus, Spain). Prof. Jordi Salas-Salvadó is partially supported by ICREA, under the ICREA Academia programme.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Legume consumption and risk of all-cause, cardiovascular, and cancer mortality in the PREDIMED study

  • Papandreou, Christopher
  • Becerra-Tomás, Nerea
  • Bulló, Mònica
  • Martínez-González, Miguel Ángel, 1957-
  • Corella, Dolores
  • Estruch, Ramón
  • Ros, Emilio
  • Arós, Fernando
  • Schröder, Helmut, 1958-
  • Fitó Colomer, Montserrat
  • Serra-Majem, Luis
  • Lapetra, José
  • Fiol, Miquel
  • Ruiz-Canela, Miguel
  • Sorlí, José Vicente
  • Salas-Salvadó, Jordi
BACKGROUND & AIMS: Limited prospective studies have examined the association between legumes consumption and mortality, whereas scarce, if at all, previous studies have evaluated such associations taking into consideration specific grain legumes. We aimed to investigate the association between total legumes consumption and grain legumes species (dry beans, chickpeas, lentils, and fresh peas) with all-cause, cardiovascular disease (CVD), cancer and other-cause mortality among elderly Mediterranean individuals at high CVD risk. METHODS: We prospectively assessed 7216 participants from the PREvención con DIeta MEDiterránea study. Dietary intake was assessed at baseline and yearly during follow-up by using a validated food frequency questionnaire. RESULTS: During a median follow-up of 6.0 years, 425 total deaths, 103 CVD deaths, 169 cancer deaths and 153 due to other-causes deaths occurred. Hazard ratios (HRs) [95% confidence interval (CI)] of CVD mortality were 1.52 (1.02-2.89) (P-trend = 0.034) and 2.23 (1.32-3.78) (P-trend = 0.002) for the 3rd tertile of total legumes and dry beans consumption, respectively, compared with the 1st tertile. When comparing extreme tertiles, higher total legumes and lentils consumption was associated with 49% (HR: 0.51; 95% CI: 0.31-0.84; P-trend = 0.009) and 37% (HR: 0.63; 95% CI: 0.40-0.98; P-trend = 0.049) lower risk of cancer mortality. Similar associations were observed for CVD death in males and for cancer death in males, obese and diabetic participants. CONCLUSIONS: These findings support the benefits of legumes consumption for cancer mortality prevention which may be counterbalanced by their higher risk for CVD mortality., Centro de Investigacion Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN) is an initiative of the Instituto de Salud Carlos III (ISCIII) of Spain which is supported by FEDER funds (CB06/03). Supported by the official funding agency for biomedical research of the Spanish government, ISCIII, through grants provided to research networks specifically developed for the trial (RTIC G03/140 and RD 06/0045 through CIBEROBN, and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigacion Sanitaria eFondo Europeo de Desarrollo Regional (PI04e2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, and PI11/02505; PI13/00462), Ministerio de Ciencia e Innovacion (AGL- 2009e13906-C02 and AGL2010e22319-C03), Fundacion Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVA-COMP2010e181, GVACOMP2011e151, CS2010- AP-111, and CS2011-AP-042), and the Navarra Regional Government (27/2011). The Fundacion Patrimonio Comunal Olivarero and Hojiblanca SA (Malaga, Spain), California Walnut Commission (Sac- ramento, CA), Borges SA (Reus, Spain), and Morella Nuts SA (Reus, Spain) donated the olive oil, walnuts, almonds, and hazelnuts, respectively, used in the study
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Alteraciones mayores del electrocardiograma y riesgo cardiovascular en la población mediterránea de medio y alto riesgo

  • Pou Bordoy, Joan
  • Leiva, Alfonso
  • Albendín Ariza, Maria José
  • Elosua Llanos, Roberto
  • Rigo Carratalà, Fernando
  • Romaguera Bosch, Dora
  • Salas Salvadó, Jordi
  • Babio, Nancy
  • Martínez-González, Miguel Ángel, 1957-
  • Toledo, Estefania
  • Fitó Colomer, Montserrat
  • Arós, Fernando
  • Estruch, Ramón
  • Fiol, Miquel
Introducción: Las alteraciones mayores del electrocardiograma (AMECG) son frecuentes en personas de mediana y avanzada edad, y podrían ser un factor importante en la predicción de eventos cardiovasculares (ECV). Objetivo: Analizar la asociación entre AMECG (clasificación de Minnesota) y ECV independientemente de los factores de riesgo cardiovascular (FRCV) clásicos y valorar si mejoran la predicción de la función de riesgo FRESCO-Función de Riesgo Española de Acontecimientos Coronarios. Método: Se incluyeron 1.752 participantes del estudio PREDIMED entre 55 y 80 años con RCV medio o alto, con una media de seguimiento de 5,1 años. Durante el periodo de seguimiento se ha estimado la incidencia acumulada de ECV por sexo y presencia de AMECG, y analizado la asociación entre AMECG y ECV mediante regresión multivariante de Cox ajustadas por grupo de aleatorización y RCV (FRESCO). Para analizar la mejora en la predicción se calcularon los índices C de Harrel's, Nam d’Agostino, Net Reclassification Improvement e Integrated Discrimination Improvement. Resultados: Al inicio del estudio, un 25% de los participantes presentaron AMECG. Durante el seguimiento aparecieron 112 ECV (16 muertes cardiovasculares, 15 infartos agudo de miocardio, 38 anginas, 43 accidentes cerebrovasculares). Las AEMCG se asociaron a una mayor probabilidad de sufrir un ECV. En varones, las principales AMECG asociadas a la aparición de ECV fueron los criterios de hipertrofia de ventrículo izquierdo (HVE) con inversión de onda T (HR: 17,88; IC 95%: 5,51-58,03; p valor < 0,001) y el alargamiento de QT (HR: 2,41; IC 95%: 1,38-4,21; p valor = 0,002), y en mujeres la fibrilación auricular (HR: 5,7; IC 95%: 1,76-18,72; p valor = 0,006) y el descenso del ST (HR: 3,24; IC 95%: 1,36-7,71; p valor < 0,001). No se observó mejoría significativa en la capacidad predictiva de FRESCO al introducir las AMECG. Conclusiones: Las AMECG se asocian de manera independiente con los ECV, por lo que deben ser consideradas durante el curso del proceso clínico. Sin embargo, no ofrece una mejora adicional en la predicción del riesgo cardiovascular a la proporcionada por los factores de riesgo clásicos., Instituto de Salud Carlos III. El ensayo PREDIMED contó con el apoyo del Instituto de Salud Carlos III (ISCIII), la agencia oficial de financiamiento para la investigación biomédica del gobierno español, a través de subvenciones otorgadas a redes de investigación específicamente desarrolladas para el ensayo (RTIC G03/140, a Ramón Estruch durante 2003-2005; RTIC RD 06/0045, a Miguel A. Martínez-González durante 2006-2013 y a través del Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBEROBN]), y mediante subvenciones del Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462 y JR17/00022) financiadas por el Ministerio de Economía y Competitividad, Instituto Carlos III y también contó con el apoyo de fondos proporcionados por la Red de Atención Primaria y promoción de la Salud (RICAPPS) RD21/0016/0009, cofinanciado con fondos de Next Generation EU, que financian las actuaciones del Mecanismo de Recuperación y Resiliencia (MRR), Ministerio de Ciencia e Innovación (AGL-2009-13906-C02, AGL2010-22319-C03, AGL2011-23430 y SAF2016-80532-R), Fundación Mapfre 2010 (sin participación en el diseño, implementación, análisis o interpretación de los datos), Consejería de Salud de la Junta de Andalucía (PI0105/2007), División de Salud Pública del Departamento de Salud de la Generalitat de Cataluña, Generalitat Valenciana (PROMETEO 17/2017 y PROMETEO 21/2021), Fundació La Marató-TV3 (subvenciones 294/C/2015 y 538/U/2016, sin participación en el diseño, implementación, análisis o interpretación de los datos)), Agencia Canaria de Investigación, Innovación y Sociedad de la Información-EU FEDER (PI 2007/050 y CS2011-AP-042), y Gobierno Regional de Navarra (P27/2011). El estudio metabolómico recibió el respaldo de la subvención de investigación NIDDK-R01DK 102896. Las donaciones de aceite de oliva, nueces, almendras y avellanas fueron realizadas, respectivamente, por la Fundación Patrimonio Comunal Olivarero y Hojiblanca (Málaga, España), California Walnut Commission (Sacramento, California), Borges (Reus, España) y Morella Nuts (Reus, España). El Prof. Jordi Salas-Salvadó cuenta con el apoyo parcial de ICREA, en el marco del programa ICREA Academia.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Dietary energy density and body weight changes after 3 years in the PREDIMED study

  • Razquin, Cristina
  • Fitó Colomer, Montserrat
  • Martínez-González, Miguel Ángel, 1957-
  • PREDIMED investigators
The association of dietary energy density (ED) and overweight is not clear in the literature. Our aim was to study in 4259 of the PREDIMED trial whether an increase in dietary ED based on a higher adherence to a Mediterranean dietary pattern was associated with 3-year weight gain. A validated 137-item food-frequency questionnaire was administered. Multivariable-adjusted models were used to analyze the association between 3-year ED change and the subsequent 3-year body weight change. The most important weight reduction after 3-year follow-up was observed in the two lowest quintiles and the highest quintile of ED change. The highest ED increase was characterized by an increased intake of extra virgin olive oil (EVOO) and nuts and a decreased intake of other oils, vegetable and fruit consumption (p < .001). In conclusion, increased 3-year ED in the PREDIMED study, associated with a higher EVOO and nuts consumption, was not associated with weight gain., The PREDIMED trial was supported by the Instituto de Salud Carlos III (ISCIII), the official funding agency for Biomedical Research of the Spanish Government, through grants provided to research networks specifically developed for the trial: RTIC G03/140, CIBERobn and RTIC RD06/0045. The authors also acknowledge grants received from Centro Nacional de Investigaciones Cardiovasculares CNIC 06/2007, Fondo de Investigación Sanitaria – Fondo Europeo de Desarrollo Regional (PI04-2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI07/0473; PI10/01407, PI11/01647, PI11/02505, PI13/00615; PI13/01090, PI14/01668, PI14/01798, and PI14/01764), Ministerio de Ciencia e Innovación (AGL-2009-13906-C02, AGL2010-22319-C03), Fundación Mapfre 2010, Public Health Division of the Department of Health of the Autonomous Government of Catalonia and Generalitat Valenciana (ACOMP06109, CS2010-AP-111 and CS2011-AP-042; GVACOMP2010-181 and GVACOMP2011-151), and a joint contract (CES09/030) with the ISCIII and the Health Department of the Catalan Government (Generalitat de Catalunya). The roles of the sponsors are as follows: the supplemental foods used in the study were generously donated by Patrimonio Comunal Olivarero and Hojiblanca from Spain (extra-virgin olive oil); the California Walnut Commission from Sacramento, CA (walnuts); and Borges S.A. (almonds) and La Morella Nuts (hazelnuts), both from Reus, Spain. However, the sponsors played no role in the design, collection, analysis, or interpretation of the data or in the decision to submit the manuscript for publication. E. Ros received research grants from the California Walnut Commission (Sacramento, CA) and is a non-paid member of its Scientific Advisory Committee. J. Salas-Salvadó received research grants from the International Nut Council (Reus, Spain) and is a non-paid member of its Scientific Advisory Committee. R. Estruch reports serving on the board of and receiving lecture fees from the Research Foundation on Wine and Nutrition (FIVIN); serving on the boards of the Beer and Health Foundation and the European Foundation for Alcohol Research (ERAB); receiving lecture fees from Cerveceros de España. R.M. Lamuela-Raventos reports serving on the board of and receiving lecture fees from FIVIN; receiving lecture fees from Cerveceros de España; and receiving lecture fees and travel support from PepsiCo. L. Serra-Majem reports serving on the boards of the Mediterranean Diet Foundation and the Beer and Health Foundation. X. Pinto´ reports serving on the board of Omegafort; receiving lecture fees from Danone; receiving payment for the development of educational presentations from Menarini; and receiving grant support through his institution from Kowa Life Science Foundation, Unilever, and Karo Bio.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Simple sugar intake and cancer incidence, cancer mortality and all-cause mortality: a cohort study from the PREDIMED trial

  • Laguna, Juan Carlos
  • Fitó Colomer, Montserrat
  • Ros, Emilio
Objective: To examine associations between intake of simple sugars and cancer incidence, cancer mortality, and total mortality in a prospective cohort study based on the PREDIMED trial conducted from 2003 to 2010. Methods: Participants were older individuals at high cardiovascular risk. Exposures were total sugar, glucose and fructose from solid or liquid sources, and fructose from fruit and 100% fruit juice. Cancer incidence was the primary outcome; cancer mortality and all-cause mortality were secondary outcomes. Multivariable-adjusted, time-dependent Cox proportional hazard models were used. Results: Of 7447 individuals enrolled, 7056 (94.7%) were included (57.6% women, aged 67.0 ± 6.2 years). 534 incident cancers with 152 cancer deaths and 409 all-cause deaths were recorded after a median follow-up of 6 years. Intake of simple sugars in solid form was unrelated to outcomes. Higher cancer incidence was found per 5 g/day increase in intake of liquid sugars, with multivariable-adjusted HR of 1.08 (95% CI, 1.03-1.13) for total liquid sugar, 1.19 (95% CI, 1.07-1.31) for liquid glucose, 1.14 (95% CI, 1.05-1.23) for liquid fructose, and 1.39 (95% CI, 1.10-1.74) for fructose from fruit juice. Cancer and all-cause mortality increased to a similar extent with intake of all sugars in liquid form. In categorical models, cancer risk was dose-related for all liquid sugars. Conclusions: Simple sugar intake in drinks and fruit juice was associated with an increased risk of overall cancer incidence and mortality and all-cause mortality. This suggests that sugary beverages are a modifiable risk factor for cancer and all-cause mortality., This work was supported by the official Spanish Institutions for funding scientific biomedical research, CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) and Instituto de Salud Carlos III (ISCIII), through the Fondo de Investigaciones Sanitarias (FIS), which is co-funded by the European Regional Development Fund (FIS projects, PI04-2239, PI05/2368, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, and P11/02505), Spanish Ministry of Economy, Industry and Competitiveness (SAF2017-82369-R, AGL-2009-13906-C02, and AGL2010-22319-C03), Generalitat de Catalunya (2017 SGR 38), Generalitat Valenciana (GV2016-141), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), and Regional Government of Navarra (P27/2011). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Lipid metabolic networks, Mediterranean diet and cardiovascular disease in the PREDIMED trial

  • Wang, Dong D.
  • Fitó Colomer, Montserrat
  • Hu, Frank B.
BACKGROUND: Perturbed lipid metabolic pathways may play important roles in the development of cardiovascular disease (CVD). However, existing epidemiological studies have focused more on discovering individual lipid metabolites for CVD risk prediction rather than assessing metabolic pathways. METHODS: This study included a subcohort of 787 participants and all 230 incident CVD cases from the PREDIMED trial. Applying a network-based analytical method, we identified lipid subnetworks and clusters from a global network of 200 lipid metabolites and linked these subnetworks/clusters to CVD risk. RESULTS: Lipid metabolites with more double bonds clustered within one subnetwork, whereas lipid metabolites with fewer double bonds clustered within other subnetworks. We identified 10 lipid clusters that were divergently associated with CVD risk. The hazard ratios [HRs, 95% confidence interval (CI)] of CVD per a 1-standard deviation (SD) increment in cluster score were 1.39 (1.17-1.66) for the hydroxylated phosphatidylcholine (HPC) cluster and 1.24 (1.11-1.37) for a cluster that included diglycerides and a monoglyceride with stearic acyl chain. Every 1-SD increase in the score of cluster that included highly unsaturated phospholipids and cholesterol esters was associated with an HR for CVD of 0.81 (95% CI, 0.67-0.98). Despite a suggestion that MedDiet modified the association between a subnetwork that included most lipids with a high degree of unsaturation and CVD, changes in lipid subnetworks/clusters during the first-year follow-up were not significantly different between intervention groups. CONCLUSIONS: The degree of unsaturation was a major determinant of the architecture of lipid metabolic network. Lipid clusters that strongly predicted CVD risk, such as the HPC cluster, warrant further functional investigations., This work was supported by a research grant from the National Institutes of Health [R01 HL118264]. The Prevención con Dieta Mediterránea (PREDIMED) trial was supported by the official funding agency for biomedical research of the Spanish government, the Instituto de Salud Carlos III, through grants provided to research networks specifically developed for the trial (RTIC G03/140 to R.E. and RTIC RD 06/0045 to Dr. Miguel A. Martínez-González) and through the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición and by grants from: the Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007); the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04–2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462); the Ministerio de Ciencia e Innovación (AGL-2009–13906-C02 and AGL2010–22319-C03); the Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007); the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVACOMP2010–181, GVACOMP2011–151, CS2010-AP-111, and CS2011-AP-042); and the Regional Government of Navarra (P27/2011). Dr. Dong D Wang was supported by a postdoctoral fellowship granted by the American Heart Association (16POST31100031)
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial

  • Martínez-González, Miguel Ángel, 1957-
  • Montero, Pedro
  • Ruiz-Canela, Miguel
  • Toledo, Estefanía
  • Estruch Riba, Ramon
  • Gómez-Gracia, Enrique
  • Li, Jun
  • Ros Rahola, Emilio
  • Arós, Fernando
  • Hernáez, Álvaro
  • Corella Piquer, Dolores
  • Fiol, Miquel
  • Lapetra, José
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Cofán Pujol, Montserrat
  • Sorlí, José V.
  • Babio, Nancy
  • Márquez-Sandoval, Yolanda F.
  • Castañer, Olga
  • Salas Salvadó, Jordi
Background Several large observational prospective studies have reported a protection by the traditional Mediterranean diet against type 2 diabetes, but none of them used yearly repeated measures of dietary intake. Repeated measurements of dietary intake are able to improve subject classification and to increase the quality of the assessed relationships in nutritional epidemiology. Beyond observational studies, randomized trials provide stronger causal evidence. In the context of a randomized trial of primary cardiovascular prevention, we assessed type 2 diabetes incidence according to yearly repeated measures of compliance with a nutritional intervention based on the traditional Mediterranean diet. Methods PREDIMED (‘‘PREvención con DIeta MEDiterránea’’) was a Spanish trial including 7447 men and women at high cardiovascular risk. We assessed 3541 participants initially free of diabetes and originally randomized to 1 of 3 diets: low-fat diet (n = 1147, control group), Mediterranean diet supplemented with extra virgin olive (n = 1154) or Mediterranean diet supplemented with mixed nuts (n = 1240). As exposure we used actual adherence to Mediterranean diet (cumulative average), yearly assessed with the Mediterranean Diet Adherence Screener (scoring 0 to 14 points), and repeated up to 8 times (baseline and 7 consecutive follow-up years). This score was categorized into four groups: < 8, 8–< 10, 10– < 12, and 12–14 points. The outcome was new-onset type 2 diabetes. Results Multivariable-adjusted hazard ratios from time-varying Cox models were 0.80 (95% confidence interval, 0.70–0.92) per + 2 points in Mediterranean Diet Adherence Screener (linear trend p = .001), and 0.46 (0.25–0.83) for the highest (12–14 points) versus the lowest (< 8) adherence. This inverse association was maintained after additionally adjusting for the randomized arm. Age- and sex-adjusted analysis of a validated plasma metabolomic signature of the Mediterranean Diet Adherence Screener (constituted of 67 metabolites) in a subset of 889 participants also supported these results. Conclusions Dietary intervention trials should quantify actual dietary adherence throughout the trial period to enhance the benefits and to assist results interpretation. A rapid dietary assessment tool, yearly repeated as a screener, was able to capture a strong inverse linear relationship between Mediterranean diet and type 2 diabetes., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts

  • Estruch, R.
  • Ros, E.
  • Salas-Salvadó, J.
  • Covas, María Isabel
  • Corella, D.
  • Arós, F.
  • Gómez-Gracia, Enrique
  • Ruiz-Gutiérrez, Valentina
  • Fiol, Miquel
  • Lapetra, José
  • Lamuela-Raventós, Rosa M.
  • Serra-Majem, L.
  • Pintó, Xavier
  • Basora, J.
  • Muñoz, M.A.
  • Sorli, J.V.
  • Martínez, J. Alfredo
  • Fitó, Montserrat
  • Gea, A.
  • Hernan, M.A.
  • Martínez-González, Miguel Ángel
BACKGROUND: Observational cohort studies and a secondary prevention trial have shown inverse associations between adherence to the Mediterranean diet and cardiovascular risk. METHODS: In a multicenter trial in Spain, we assigned 7447 participants (55 to 80 years of age, 57% women) who were at high cardiovascular risk, but with no cardiovascular disease at enrollment, to one of three diets: a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control diet (advice to reduce dietary fat). Participants received quarterly educational sessions and, depending on group assignment, free provision of extra-virgin olive oil, mixed nuts, or small nonfood gifts. The primary end point was a major cardiovascular event (myocardial infarction, stroke, or death from cardiovascular causes). After a median follow-up of 4.8 years, the trial was stopped on the basis of a prespecified interim analysis. In 2013, we reported the results for the primary end point in the Journal. We subsequently identified protocol deviations, including enrollment of household members without randomization, assignment to a study group without randomization of some participants at 1 of 11 study sites, and apparent inconsistent use of randomization tables at another site. We have withdrawn our previously published report and now report revised effect estimates based on analyses that do not rely exclusively on the assumption that all the participants were randomly assigned. RESULTS: A primary end-point event occurred in 288 participants; there were 96 events in the group assigned to a Mediterranean diet with extra-virgin olive oil (3.8%), 83 in the group assigned to a Mediterranean diet with nuts (3.4%), and 109 in the control group (4.4%). In the intention-to-treat analysis including all the participants and adjusting for baseline characteristics and propensity scores, the hazard ratio was 0.69 (95% confidence interval [CI], 0.53 to 0.91) for a Mediterranean diet with extra-virgin olive oil and 0.72 (95% CI, 0.54 to 0.95) for a Mediterranean diet with nuts, as compared with the control diet. Results were similar after the omission of 1588 participants whose study-group assignments were known or suspected to have departed from the protocol. CONCLUSIONS: In this study involving persons at high cardiovascular risk, the incidence of major cardiovascular events was lower among those assigned to a Mediterranean diet supplemented with extra-virgin olive oil or nuts than among those assigned to a reduced-fat diet., Supported by Instituto de Salud Carlos III, Spanish Ministry of Health, through grants provided to research networks specifically developed for the study (RTIC G03/140, to Dr. Estruch, and RTIC RD 06/0045, to Dr. Martínez-González); Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición; and grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, and P11/02505), Ministerio de Ciencia e Innovación (AGL-2009-13906-C02 and AGL2010-22319-C03), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVACOMP2010-181, GVACOMP2011-151, CS2010-AP-111, and CS2011-AP-042), and Regional Government of Navarra (P27/2011). Dr. Hernán was supported by a grant (ME-1503-28119) from the Patient-Centered Outcomes Research Institute., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery of human urinary biomarkers of aronia-citrus juice intake by HPLC-q-TOF-based metabolomic approach

  • Llorach, Rafael
  • Medina Escudero, Sonia
  • García-Viguera, Cristina
  • Zafrilla, Pilar
  • Abellán, José
  • Jauregui, Olga
  • Tomás Barberán, Francisco
  • Gil-Izquierdo, Ángel
  • Andrés-Lacueva, Cristina
Metabolomics has emerged in the field of food and nutrition sciences as a powerful tool for doing profiling approaches. In this context, HPLC-q-TOF-based metabolomics approach was applied to unveil changes in the urinary metabolome in human subjects (n = 51, 23 men and 28 women) after regular aronia-citrus juice (AC-juice) intake (250 mL/day) during 16 weeks compared to individuals given a placebo beverage. Samples were analyzed by HPLC-q-TOF followed by multivariate data analysis (orthogonal signal filtering-partial least square discriminant analysis) that discriminated relevant mass features related to AC-juice intake. The results showed that biomarkers of AC-juice intake including metabolites coming from metabolism of food components as proline betaine, ferulic acid, and two unknown mercapturate derivatives were identified. Discovery of new biomarkers of food intake will help in the building up of the food metabolome and facilitate future insights into the mechanisms of action of dietary components in population health, The authors are grateful to the National funding agencies through the Project CSD007-0063 (CONSOLIDER-INGENIO 2010 ‘Fun-C-Food', AGL2009-13906-C02-01 AGL2011-23690 and CSIC 201170E041), Spanish Ministry of Economy and Competitiveness. R.Ll. thanks the “Ramon y Cajal ́” program of the Spanish Ministry of Science and Innovation (MICINN) and Fondo Social Europeo (FSE) (RYC-2010-07334). SME was granted a predoctoral CSIC-JAE fellowship, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dietary Inflammatory Index and Incidence of Cardiovascular Disease in the PREDIMED Study

  • García-Arellano, Ana
  • Ramallal, Raul
  • Ruiz-Canela, Miguel
  • Salas-Salvadó, Jordi
  • Corella, Dolores
  • Shivappa, Nitin
  • Schröder, Helmut
  • Hébert, James R.
  • Ros, Emilio
  • Gómez-García, Enrique
  • Estruch, Ramon
  • Lapetra, José
  • Arós, Fernando
  • Fiol, Miquel
  • Serra-Majem, Lluis
  • Pintó, Xavier
  • Babio, Nancy
  • González, José I.
  • Fitó, Montserrat
  • Martínez, J. Alfredo
  • Martínez-González, Miguel A.
  • PREMIDED investigators
  • Santos-Lozano, J. M.
  • Leal, Manuel
  • Martínez, E.
  • Ortega-Calvo, Manuel
  • Román, P.
  • García, F. José
  • Iglesias, Pablo
  • Corchado, Y.
  • Mayoral, E.
  • Mellado, L.
  • Miró, L.
  • Lozano, J. M.
  • Lama, C.
This article belongs to the Special Issue Nutrition and CVD, Previous studies have reported an association between a more pro-inflammatory diet profile and various chronic metabolic diseases. The Dietary Inflammatory Index (DII) was used to assess the inflammatory potential of nutrients and foods in the context of a dietary pattern. We prospectively examined the association between the DII and the incidence of cardiovascular disease (CVD: myocardial infarction, stroke or cardiovascular death) in the PREDIMED (Prevención con Dieta Mediterránea) study including 7216 high-risk participants. The DII was computed based on a validated 137-item food frequency questionnaire. Multivariate-adjusted hazard ratios (HR) and 95% confidence intervals of CVD risk were computed across quartiles of the DII where the lowest (most anti-inflammatory) quartile is the referent. Risk increased across the quartiles (i.e., with increasing inflammatory potential): HRquartile2 = 1.42 (95%CI = 0.97–2.09); HRquartile3 = 1.85 (1.27–2.71); and HRquartile4 = 1.73 (1.15–2.60). When fit as continuous the multiple-adjusted hazard ratio for each additional standard deviation of the DII was 1.22 (1.06–1.40). Our results provide direct prospective evidence that a pro-inflammatory diet is associated with a higher risk of cardiovascular clinical events., This research was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140, to RE; RTIC RD 06/0045, to MAM-G) and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (Proyecto de Investigación (PI) 04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462), the Ministerio de Ciencia e Innovación (Recursos y teconologia agroalimentarias (AGL)-2009-13906-C02 and AGL2010-22319-C03 and AGL2013-49083-C3-1-R), the Fundación Mapfre 2010, the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, the Generalitat Valenciana (Generalitat Valenciana Ayuda Complementatia (GVACOMP) 06109, GVACOMP2010-181, GVACOMP2011-151), Conselleria de Sanitat y AP; Atención Primaria (CS) 2010-AP-111, and CS2011-AP-042), Regional Government of Navarra (P27/2011), and Centre Català de la Nutrició de l'Institut d'Estudis Catalans. ET is supported by a Rio Hortega post-residency fellow of the Instituto de Salud Carlos III, Ministry of Economy and Competitiveness, Spanish Government., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Does the Mediterranean diet counteract the adverse effects of abdominal adiposity?

  • Eguaras, S.
  • Toledo, E.
  • Buil-Cosiales, P.
  • Salas-Salvadó, Jordi
  • Corella, Dolores
  • Gutiérrez-Bedmar, M.
  • Santos-Lozano, J. M.
  • Arós, Fernando
  • Fiol, Miquel
  • Fitó, Montserrat
  • Ros, Emilio
  • Serra-Majem, Lluis
  • Pintó, Xavier
  • Martínez, J. Alfredo
  • Sorlí, José V.
  • Muñoz, María A.
  • Basora, Josep
  • Estruch, Rramón
  • Martínez-González, Miguel Ángel
  • PREDIMED Investigators
[Background and aim] We tested the hypothesis that an intervention with a Mediterranean diet (MeDiet) could mitigate the well-known harmful effects of abdominal obesity on cardiovascular health., [Methods and results] We assessed the relationship between baseline waist-to-height ratio (WHtR) and major cardiovascular events during a median follow-up of 4.8 years in the Prevention with Mediterranean Diet (PREDIMED) randomized primary prevention trial, which tested a MeDiet against a control diet (advice on a low-fat diet). We also examined whether the MeDiet intervention was able to counteract the detrimental cardiovascular effects of an increased WHtR. The trial included 7447 participants (55–80 years old, 57% women) at high cardiovascular risk but free of cardiovascular disease (CVD) at enrollment., An increased risk of CVD events (myocardial infarction, stroke, or cardiovascular death) was apparent for the highest versus the lowest quartile of WHtR (multivariable-adjusted hazard ratio: 1.98) (95% confidence interval: 1.10–3.57; linear trend: p = 0.019) only in the control-diet group, but not in the two groups allocated to intervention with MeDiet (p for interaction = 0.034). This apparent interaction suggesting that the intervention counterbalanced the detrimental cardiovascular effects of adiposity was also significant for body mass index (BMI) (p = 0.01) and waist circumference (p = 0.043)., [Conclusions] The MeDiet may counteract the harmful effects of increased adiposity on the risk of CVD., Supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through specific grants (RTIC G03/140; RTIC-RD 06/0045, to Prof. Martínez-González and CIBERobn), and by Fondo de Investigación Sanitaria–ISCIII (PI04-2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, and P11/02505), Ministerio Ciencia e Innovación (AGL-2009-13906-C02 and AGL2010-22319-C03), Fundación Mapfre 2010, Consejería Salud Junta de Andalucía (PI0105/2007), Health Department of Catalonia, Generalitat Valenciana (ACOMP06109, GVACOMP2010-181, GVACOMP2011-151, CS2010-AP-111, and CS2011-AP-042), and Regional Government of Navarra (P27/2011). ET is supported by a Rio Hortega post-residency fellow of the ISCIII., Peer reviewed
O2, repositorio institucional de la UOC
Publicación Artículo científico (JournalArticle)

Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: A randomized clinical trial

  • Chiva-Blanch, Gemma
  • urpi, mireia
  • Ros, Emilio
  • llorach, rafael
  • Andres-Lacueva, Cristina
  • Estruch Riba, Ramón
  • Lamuela-Raventos, Rosa M
  • Valderas-Martínez, Palmira
  • Casas, Rosa
  • Arranz, Sara
  • Marisa, Guillén
Background & aims. Epidemiological data suggest that moderate red wine consumption reduces cardiovascular mortality and the incidence of diabetes. However, whether these effects are due to ethanol or to non-alcoholic components of red wine still remains unknown. The aim of the present study was to compare the effects of moderate consumption of red wine, dealcoholized red wine, and gin on glucose metabolism and the lipid profile. Methods. Sixty-seven men at high cardiovascular risk were randomized in a crossover trial. After a run-in period, all received each of red wine (30 g alcohol/d), the equivalent amount of dealcoholized red wine, and gin (30 g alcohol/d) for 4 week periods, in a randomized order. Fasting plasma glucose and insulin, homeostasis model assessment of insulin resistance (HOMA-IR), plasma lipoproteins, apolipoproteins and adipokines were determined at baseline and after each intervention. Results. Fasting glucose remained constant throughout the study, while mean adjusted plasma insulin and HOMA-IR decreased after red wine and dealcoholized red wine. HDL cholesterol, Apolipoprotein A-I and A-II increased after red wine and gin. Lipoprotein(a) decreased after the red wine intervention. Conclusions. These results support a beneficial effect of the non-alcoholic fraction of red wine (mainly polyphenols) on insulin resistance, conferring greater protective effects on cardiovascular disease to red wine than other alcoholic beverages.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dietary energy density and body weight changes after 3 years in the PREDIMED study

  • Razquin, Cristina
  • Fitó Colomer, Montserrat
  • Martínez-González, Miguel Ángel, 1957-
  • PREDIMED investigators
The association of dietary energy density (ED) and overweight is not clear in the literature. Our aim was to study in 4259 of the PREDIMED trial whether an increase in dietary ED based on a higher adherence to a Mediterranean dietary pattern was associated with 3-year weight gain. A validated 137-item food-frequency questionnaire was administered. Multivariable-adjusted models were used to analyze the association between 3-year ED change and the subsequent 3-year body weight change. The most important weight reduction after 3-year follow-up was observed in the two lowest quintiles and the highest quintile of ED change. The highest ED increase was characterized by an increased intake of extra virgin olive oil (EVOO) and nuts and a decreased intake of other oils, vegetable and fruit consumption (p < .001). In conclusion, increased 3-year ED in the PREDIMED study, associated with a higher EVOO and nuts consumption, was not associated with weight gain., The PREDIMED trial was supported by the Instituto de Salud Carlos III (ISCIII), the official funding agency for Biomedical Research of the Spanish Government, through grants provided to research networks specifically developed for the trial: RTIC G03/140, CIBERobn and RTIC RD06/0045. The authors also acknowledge grants received from Centro Nacional de Investigaciones Cardiovasculares CNIC 06/2007, Fondo de Investigación Sanitaria – Fondo Europeo de Desarrollo Regional (PI04-2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI07/0473; PI10/01407, PI11/01647, PI11/02505, PI13/00615; PI13/01090, PI14/01668, PI14/01798, and PI14/01764), Ministerio de Ciencia e Innovación (AGL-2009-13906-C02, AGL2010-22319-C03), Fundación Mapfre 2010, Public Health Division of the Department of Health of the Autonomous Government of Catalonia and Generalitat Valenciana (ACOMP06109, CS2010-AP-111 and CS2011-AP-042; GVACOMP2010-181 and GVACOMP2011-151), and a joint contract (CES09/030) with the ISCIII and the Health Department of the Catalan Government (Generalitat de Catalunya). The roles of the sponsors are as follows: the supplemental foods used in the study were generously donated by Patrimonio Comunal Olivarero and Hojiblanca from Spain (extra-virgin olive oil); the California Walnut Commission from Sacramento, CA (walnuts); and Borges S.A. (almonds) and La Morella Nuts (hazelnuts), both from Reus, Spain. However, the sponsors played no role in the design, collection, analysis, or interpretation of the data or in the decision to submit the manuscript for publication. E. Ros received research grants from the California Walnut Commission (Sacramento, CA) and is a non-paid member of its Scientific Advisory Committee. J. Salas-Salvadó received research grants from the International Nut Council (Reus, Spain) and is a non-paid member of its Scientific Advisory Committee. R. Estruch reports serving on the board of and receiving lecture fees from the Research Foundation on Wine and Nutrition (FIVIN); serving on the boards of the Beer and Health Foundation and the European Foundation for Alcohol Research (ERAB); receiving lecture fees from Cerveceros de España. R.M. Lamuela-Raventos reports serving on the board of and receiving lecture fees from FIVIN; receiving lecture fees from Cerveceros de España; and receiving lecture fees and travel support from PepsiCo. L. Serra-Majem reports serving on the boards of the Mediterranean Diet Foundation and the Beer and Health Foundation. X. Pinto´ reports serving on the board of Omegafort; receiving lecture fees from Danone; receiving payment for the development of educational presentations from Menarini; and receiving grant support through his institution from Kowa Life Science Foundation, Unilever, and Karo Bio.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Plasma lipidome and risk of atrial fibrillation: results from the PREDIMED trial

  • Toledo, Estefania
  • Fitó Colomer, Montserrat
  • Martínez-González, Miguel Ángel, 1957-
The potential role of the lipidome in atrial fibrillation (AF) development is still widely unknown. We aimed to assess the association between lipidome profiles of the Prevención con Dieta Mediterránea (PREDIMED) trial participants and incidence of AF. We conducted a nested case-control study (512 incident centrally adjudicated AF cases and 735 controls matched by age, sex, and center). Baseline plasma lipids were profiled using a Nexera X2 U-HPLC system coupled to an Exactive Plus orbitrap mass spectrometer. We estimated the association between 216 individual lipids and AF using multivariable conditional logistic regression and adjusted the p values for multiple testing. We also examined the joint association of lipid clusters with AF incidence. Hitherto, we estimated the lipidomics network, used machine learning to select important network-clusters and AF-predictive lipid patterns, and summarized the joint association of these lipid patterns weighted scores. Finally, we addressed the possible interaction by the randomized dietary intervention.Forty-one individual lipids were associated with AF at the nominal level (p < 0.05), but no longer after adjustment for multiple-testing. However, the network-based score identified with a robust data-driven lipid network showed a multivariable-adjusted ORper+1SD of 1.32 (95% confidence interval: 1.16-1.51; p < 0.001). The score included PC plasmalogens and PE plasmalogens, palmitoyl-EA, cholesterol, CE 16:0, PC 36:4;O, and TG 53:3. No interaction with the dietary intervention was found. A multilipid score, primarily made up of plasmalogens, was associated with an increased risk of AF. Future studies are needed to get further insights into the lipidome role on AF.Current Controlled Trials number, ISRCTN35739639., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This study was supported by the National Institutes of Health grants R01HL118264 and R01DK102896. The PREDIMED trial (Prevención con Dieta Mediterránea) was supported by the official funding agency for biomedical research of the Spanish government, the Instituto de Salud Carlos III, through the grant coordinated by MAMG for a research network specifically developed during 2006-2013 for the trial (RTIC RD 06/0045) and a previous grant coordinated by RE (RTIC G03/140) during 2003-2005 and through the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición and by grants from: the Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007); the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04–2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, and PI13/00462); the Ministerio de Ciencia e Investigación (AGL-2009–13906-C02 and AGL2010–22319-C03); the Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007); the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVA-COMP2010–181, GVACOMP2011–151, CS2010-AP-111, and CS2011-AP-042); the Regional Government of Navarra (P27/2011); and the European Union in the frame of the Joint Programming Initiative ‘A Healthy Diet for a Healthy Life’ to the Fatty Acid Metabolism—Interlinking Diet with Cardiometabolic Health (FAME)-consortium (01EA1704). J. Salas-Salvadó, gratefully acknowledges the financial support by ICREA under the ICREA Academia programme. C. Wittenbecher was supported by an individual fellowship from the German Research Foundation (DFG).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Association between the 2018 WCRF/AICR and the low-risk lifestyle scores with colorectal cancer risk in the Predimed Study

  • Barrubés, Laura
  • Babio, Nancy
  • Hernández-Alonso, Pablo
  • Toledo, Estefania
  • Estruch, Ramón
  • Ros, Emilio
  • Fitó Colomer, Montserrat
  • Alonso-Gómez, Ángel
  • Fiol, Miquel
  • Lapetra, José
  • Serra-Majem, Luis
  • Pintó Sala, Xavier
  • Ruiz-Canela, Miguel
  • Corella, Dolores
  • Castañer, Olga
  • Macías-González, Manuel
  • Salas Salvadó, Jordi
Limited longitudinal studies have been conducted to evaluate colorectal cancer (CRC) incidence based on the updated 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) recommendations or other global lifestyle indices, and none in aged populations at high cardiovascular risk. We aimed to assess the association between CRC incidence and adherence to two emerging lifestyles indices (2018 WCRF/AICR score and another low-risk lifestyle (LRL) score comprising smoking status, alcohol consumption, physical activity, diet, and body mass index) in the Spanish PREvencion con DIeta MEDiterranea (PREDIMED) cohort. We studied 7216 elderly men and women at high cardiovascular risk. The 2018 WCRF/AICR and LRL scores were calculated. Multivariable Cox proportional regression models were fitted to estimate the HRs (hazard ratios) and 95% confidence intervals (CIs) for incident CRC events. During a median interquartile range (IQR) follow-up of 6.0 (4.4-7.3) years, 97 CRC events were considered. A significant linear association was observed between each 1-point increment in the WCRF/AICR score (score range from 0 to 7) and CRC risk (HR (95% CI) = 0.79 (0.63-0.99)). Similarly, each 1-point increment in the LRL score (score range from 0 to 5) was associated with a 22% reduction in CRC risk (0.78 (0.64-0.96)). Adhering to emergent lifestyle scores might substantially reduce CRC incidence in elderly individuals. Further longitudinal studies, which take different lifestyle indexes into account, are warranted in the future., The Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN) is an initiative of the Spanish Instituto de Salud Carlos III (ISCIII) which is funded by FEDER “A way to make Europe”/”Investing in your future” (CB06/03). It is supported by the official funding agency for biomedical research of the Spanish government, ISCIII, through grants provided to research networks specifically developed for the trial (RTIC G03/140 and RD 06/0045) through CIBEROBN, and by grants from the Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04–2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI07/0473, PI10/01407, PI10/02658, PI11/01647, and PI11/02505; PI13/00462), Ministerio de Ciencia e Innovación (AGL-2009–13906-C02 and AGL2010–22319-C03), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (PROMETEO17/2017), and the Navarra Regional Government (27/2011). The Fundación Patrimonio Comunal Olivarero and Hojiblanca SA (Málaga, Spain), California Walnut Commission (Sacramento, CA), Borges SA (Reus, Spain), and Morella Nuts SA (Reus, Spain) donated the olive oil, walnuts, almonds, and hazelnuts, respectively, used in the study. J. Salas-Salvadó, the senior author/gratefully acknowledges the financial support by ICREA under the ICREA Academia program. Dr. P.H.-A. is supported by a postdoctoral fellowship (Juan de la Cierva-Formación, FJCI-2017-32205). L. Barrubés has been awarded a grant by the Spanish Ministry of Education, Culture, and Sports (FPU 16/00165). M.M.-G. was the recipient of the Nicolas Monardes Programme from the “Servicio Andaluz de Salud, Junta de Andalucía”, Spain (RC-0001-2018 and C-0029-2023). None of the funding sources played a role in the design, collection, analysis or interpretation of the data or in the decision to submit the manuscript for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Serum selenium and incident cardiovascular disease in the PREvención con DIeta MEDiterránea (PREDIMED) trial: Nested case-control study

  • Gutiérrez Bedmar, Mario
  • Gil, Fernando
  • Olmedo, Pablo
  • Ruiz-Canela, Miguel
  • Martínez-González, Miguel Ángel, 1957-
  • Salas Salvadó, Jordi
  • Babio, Nancy
  • Fitó Colomer, Montserrat
  • Val, José Luis del
  • Corella, Dolores
  • Sorlí, José Vicente
  • Ros, Emilio
  • Fiol, Miquel
  • Estruch, Ramón
  • Santos-Lozano, José
  • Arós, Fernando
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Gómez-Gracia, Enrique
  • Muñoz-Bravo, Carlos
Background: Selenium is an essential trace mineral with potential interest for cardiovascular disease (CVD) prevention owing to its antioxidant properties. Epidemiological data on selenium status and CVD remain inconsistent. The objective of this study was to ascertain whether low serum selenium (SSe) concentrations are related to an increased risk of a first CVD event in a population at high cardiovascular risk. Methods: We undertook a case-control study nested within the “PREvención con DIeta MEDiterránea” (PREDIMED) trial. A total of 207 participants diagnosed with CVD (myocardial infarction, stroke, or cardiovascular death) during the follow-up period (2003−2010) were matched by sex, age, and intervention group to 436 controls by incidence density sampling. Median time between serum sample collection and subsequent CVD event occurrence was 0.94 years. SSe levels were determined using inductively coupled plasma mass spectrometry analysis. Covariates were assessed through validated questionnaires, in-person interviews, and medical record reviews. Conditional logistic regression was used to calculate multivariable-adjusted odds ratios (ORs). Results: Among women, the mean SSe concentration was lower in cases than in controls (98.5 μg/L vs. 103.8 μg/L; p = 0.016). In controls, SSe levels were directly associated with percentage of total energy intake from proteins and fish intake (p for linear trend < 0.001 and 0.049, respectively), whereas SSe concentrations were inversely associated with age, body mass index, and percentage of total energy intake from carbohydrates (p for linear trend < 0.001, 0.008 and 0.016 respectively). In the total group, we observed an inverse dose−response gradient between SSe levels and risk of CVD in the fully-adjusted model (highest vs. lowest quartile: OR = 0.47, 95% CI: 0.27−0.81; ptrend = 0.003). Conclusions: Among elderly individuals at high cardiovascular risk, high SSe concentrations within population reference values are associated with lower first CVD incidence., This research was funded by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140; RTIC RD 06/0045 “PREDIMED”), and JR14/00008, and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (Proyecto de Investigación (PI04-2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462), the Ministerio de Ciencia e Innovación (Recursos y teconologia agroalimentarias (AGL)-2009-13906-C02 and AGL2010-22319-C03 and AGL2013-49083C3-1-R), the Ministerio de Economía y Competitividad-Fondos FEDER-Instituto de Salud Carlos III (UNGR15-CE-3380), the Fundación Mapfre 2010, the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, the Generalitat Valenciana Ayuda Complementatia GVACOMP 06109, GVACOMP2010-181, GVACOMP2011-151, PROMETEO 21/2021, Conselleria de Sanitat y Atención Primaria CS2010-AP-111, and CS2011-AP-042, Regional Government of Navarra (P27/2011), and Centre Català de la Nutrició de l’Institut d’Estudis Catalans. Hojiblanca and Patrimonio Communal Olivarero donated extra-virgin olive oil; the California Walnut Commission donated walnuts; Borges donated almonds; La Morella Nuts donated hazelnuts.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Association between serum copper levels and risk of cardiovascular disease: A nested case-control study in the PREDIMED trial

  • Muñoz-Bravo, Carlos
  • Olmedo, Pablo
  • Gil, Fernando
  • Ruiz-Canela, Miguel
  • Martínez-González, Miguel Ángel, 1957-
  • Martínez, María Ángeles
  • Babio, Nancy
  • Fitó Colomer, Montserrat
  • Val, José Luis del
  • Corella, Dolores
  • Sorlí, José Vicente
  • Ros, Emilio
  • Fiol, Miquel
  • Estruch, Ramón
  • Santos Lozano, José Manuel
  • Arós, Fernando
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Gómez Gracia, Enrique
  • Gutiérrez Bedmar, Mario
Background and aim: Certain trace elements have been associated with increased cardiovascular risk. The aim of this study was to evaluate the association between serum copper (S-Cu) levels and the risk of a first event of cardiovascular disease (CVD) in a population of older adults with high cardiovascular risk. Methods and results: We conducted a case-control study nested within the PREDIMED trial. During a median follow-up of 4.8 years, a total of 207 incident cases diagnosed with CVD were matched for sex, age, and intervention group with 436 controls. Personal interviews, reviews of medical records, and validated questionnaires were used to assess known CVD risk factors. Biological serum samples were collected annually. Inductively coupled plasma mass spectrometry analysis was used to determine S-Cu levels. Adjusted odds ratios were calculated using multivariate conditional logistic regression models. All participants had S-Cu levels within the reference values, 750 μg/L to 1450 μg/L. Among men, but not among women, the mean S-Cu concentration was higher in cases 1014.1 μg/L than in controls 959.3 μg/L; (p = 0.004). In men, the multivariable-adjusted odds ratio for CVD was 2.36 (95% CI 1.07-5.20 for the comparison of the highest vs. the lowest quartile; p for trend = 0.02), in women, it was 0.43 (95% CI 0.11-1.70; p for trend = 0.165). Conclusion: In older Spanish men with high cardiovascular risk, a significant association was observed between high S-Cu levels, but still within the reference values, and an increased risk of a first event of CVD. Our findings suggest a sex difference in CVD risk and S-Cu levels. To confirm this relationship and to analyze the differences observed between men and women, further studies are needed., This research was funded by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140; RTIC RD 06/0045 “PREDIMED”), and JR14/00008, and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC06/2007), the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (Proyecto de Investigación (PI04-2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462), the Ministerio de Ciencia e Innovación (Recursos y teconologia agroalimentarias (AGL)-2009-13906-C02 and AGL2010-22319-C03 and AGL2013-49083C3-1-R), the Ministerio de Economía y Competitividad-Fondos FEDER-Instituto de Salud Carlos III (UNGR15-CE-3380), the Fundación Mapfre 2010, the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, the Generalitat Valenciana (Generalitat Valenciana Ayuda Complementatia GVACOMP) 06109, GVACOMP2010-181, GVACOMP2011-151), Conselleria de Sanitat y AP; Atención Primaria (CS) 2010-AP-111, and CS2011-AP-042), Regional Government of Navarra (P27/2011), and Centre Català de la Nutrició de l'Institut d'Estudis Catalans. Hojiblanca and Patrimonio Communal Olivarero donated extra-virgin olive oil; the California Walnut Commission donated walnuts; Borges donated almonds; La Morella Nuts donated hazelnuts.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Low serum iron levels and risk of cardiovascular disease in high risk elderly population: Nested case-control study in the PREvención con DIeta MEDiterránea (PREDIMED) trial

  • Gutierrez Bedmar, Mario
  • Olmedo, Pablo
  • Gil, Fernando
  • Ruiz-Canela, Miguel
  • Martínez-González, Miguel Ángel, 1957-
  • Salas Salvadó, Jordi
  • Babio, Nancy
  • Fitó Colomer, Montserrat
  • Val, José Luis del
  • Corella, Dolores
  • Sorlí, José Vicente
  • Ros, Emilio
  • Fiol, Miquel
  • Estruch, Ramón
  • Lapetra, José
  • Arós, Fernando
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Gómez Gracia, Enrique
Background & aims: Epidemiological data on iron status and cardiovascular disease (CVD) are still controversial. The aim of this study was to determine whether low serum iron (SI) levels are associated with an increased odds of first CVD event in a population at high cardiovascular risk. Methods: Case-control study design nested within the "PREvención con DIeta MEDiterránea" (PREDIMED) trial. A total of 207 participants diagnosed with CVD (myocardial infarction, stroke or cardiovascular death) during follow-up period (2003-2010) were matched by sex, age and intervention group to 436 controls by incidence density sampling. Median time between serum sample collection and subsequent CVD event occurrence was 0.94 years. Inductively coupled plasma mass spectrometry analysis was used to determine SI levels. In-person interviews, medical record reviews, and validated questionnaires were used to assess covariates. Multivariable-adjusted odds ratios (ORs) of CVD were calculated with conditional logistic regression. Results: Mean SI levels were higher in men than in women (1224.0 μg/L vs. 1093.8 μg/L; p < 0.001). Among women, but not in men, the mean SI concentration was lower in cases than in controls (1008.5 μg/L vs. 1132.9 μg/L; p = 0.030). There was a gradual decrease in the multivariable-adjusted ORs of CVD with increasing SI levels (highest vs. lowest quartile: OR = 0.55, 95% CI: 0.32-0.93; ptrend = 0.020). This inverse relationship was more pronounced among women (highest vs. lowest quartile: OR = 0.15, 95% CI: 0.03-0.69; ptrend = 0.011). Conclusions: The present findings are consistent with previously reported inverse associations between SI and CVD. SI levels as an independent marker of short-term cardiovascular risk may be useful for risk assessment in older populations. Trial registration: www.controlled-trials.com; International Standard Randomized Controlled Trial Number (ISRCTN): 35,739,639. Registered 5 October 2005. Retrospectively registered., This research was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140; RTIC RD 06/0045 “PREDIMED”), and JR14/00008, and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (Proyecto de Investigación (PI04-2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462), the Ministerio de Ciencia e Innovación (Recursos y teconologia agroalimentarias (AGL)-2009-13906-C02 and AGL2010-22319-C03 and AGL2013-49083C3-1-R), the Ministerio de Economía y Competitividad-Fondos FEDER-Instituto de Salud Carlos III (UNGR15-CE-3380), the Fundación Mapfre 2010, the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, the Generalitat Valenciana (Generalitat Valenciana Ayuda Complementatia GVACOMP) 06109, GVACOMP2010-181, GVACOMP2011-151), Conselleria de Sanitat y AP; Atención Primaria (CS) 2010-AP-111, and CS2011-AP-042), Regional Government of Navarra (P27/2011), and Centre Català de la Nutrició de l'Institut d'Estudis Catalans. Hojiblanca and Patrimonio Communal Olivarero donated extra-virgin olive oil; the California Walnut Commission donated walnuts; Borges donated almonds; La Morella Nuts donated hazelnuts. ROLE OF THE FUNDERS: funding sources had no role in the designing and conducting of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Plasma Metabolites From Choline Pathway and Risk of Cardiovascular Disease in the PREDIMED (Prevention With Mediterranean Diet) Study

  • Guasch-Ferré, Marta
  • Hu, Frank B.
  • Ruiz-Canela, Miguel
  • Bulló, Mònica
  • Toledo, Estefania
  • Wang, Dong D.
  • Corella, Dolores
  • Gómez Gracia, Enrique
  • Fiol, Miquel
  • Estruch, Ramón
  • Lapetra, José
  • Fitó Colomer, Montserrat
  • Arós, Fernando
  • Serra-Majem, Luis
  • Ros, Emilio
  • Dennis, Courtney
  • Liang, Liming
  • Clish, Clary B.
  • Martínez-González, Miguel Ángel, 1957-
  • Salas-Salvadó, Jordi
BACKGROUND: The relationship between plasma concentrations of betaine and choline metabolism and major cardiovascular disease (CVD) end points remains unclear. We have evaluated the association between metabolites from the choline pathway and risk of incident CVD and the potential modifying effect of Mediterranean diet interventions. METHODS AND RESULTS: We designed a case-cohort study nested within the PREDIMED (Prevention With Mediterranean Diet) trial, including 229 incident CVD cases and 751 randomly selected participants at baseline, followed up for 4.8 years. We used liquid chromatography-tandem mass spectrometry to measure, at baseline and at 1 year of follow-up, plasma concentrations of 5 metabolites in the choline pathway: trimethylamine N-oxide, betaine, choline, phosphocholine, and α-glycerophosphocholine. We have calculated a choline metabolite score using a weighted sum of these 5 metabolites. We used weighted Cox regression models to estimate CVD risk. The multivariable hazard ratios (95% confidence intervals) per 1-SD increase in choline and α-glycerophosphocholine metabolites were 1.24 (1.05-1.46) and 1.24 (1.03-1.50), respectively. The baseline betaine/choline ratio was inversely associated with CVD. The baseline choline metabolite score was associated with a 2.21-fold higher risk of CVD across extreme quartiles (95% confidence interval, 1.36-3.59; P<0.001 for trend) and a 2.27-fold higher risk of stroke (95% confidence interval, 1.24-4.16; P<0.001 for trend). Participants in the higher quartiles of the score who were randomly assigned to the control group had a higher risk of CVD compared with participants in the lower quartile and assigned to the Mediterranean diet groups (P=0.05 for interaction). No significant associations were observed for 1-year changes in individual plasma metabolites and CVD. CONCLUSIONS: A metabolite score combining plasma metabolites from the choline pathway was associated with an increased risk of CVD in a Mediterranean population at high cardiovascular risk., This work was supported by NIH research grant HL118264. The PREDIMED trial was supported by the official funding agency for biomedical research of the Spanish Government, Instituto de Salud Carlos III, through grants provided to research networks specifically developed for the trial (RTIC G03/140 to Estruch; RTIC RD 06/0045 to Martínez‐González) and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición; and by grants from Centro Nacional de Investigaciones Cardiovasculares (06/2007), Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04–2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, and PI13/00462), Ministerio de Ciencia e Innovación (AGL‐2009–13906‐C02 and AGL2010–22319‐C03), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVA‐COMP2010–181, GVACOMP2011–151, CS2010‐AP‐111, and CS2011‐AP‐042), and Regional Government of Navarra (P27/2011). Guasch‐Ferré was supported by a postdoctoral fellowship granted by the Agency for Administration of University and Research Grants of the Autonomous Government of Catalonia (2014‐BP‐A 00017).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Legume consumption and risk of all-cause, cardiovascular, and cancer mortality in the PREDIMED study

  • Papandreou, Christopher
  • Becerra-Tomás, Nerea
  • Bulló, Mònica
  • Martínez-González, Miguel Ángel, 1957-
  • Corella, Dolores
  • Estruch, Ramón
  • Ros, Emilio
  • Arós, Fernando
  • Schröder, Helmut, 1958-
  • Fitó Colomer, Montserrat
  • Serra-Majem, Luis
  • Lapetra, José
  • Fiol, Miquel
  • Ruiz-Canela, Miguel
  • Sorlí, José Vicente
  • Salas-Salvadó, Jordi
BACKGROUND & AIMS: Limited prospective studies have examined the association between legumes consumption and mortality, whereas scarce, if at all, previous studies have evaluated such associations taking into consideration specific grain legumes. We aimed to investigate the association between total legumes consumption and grain legumes species (dry beans, chickpeas, lentils, and fresh peas) with all-cause, cardiovascular disease (CVD), cancer and other-cause mortality among elderly Mediterranean individuals at high CVD risk. METHODS: We prospectively assessed 7216 participants from the PREvención con DIeta MEDiterránea study. Dietary intake was assessed at baseline and yearly during follow-up by using a validated food frequency questionnaire. RESULTS: During a median follow-up of 6.0 years, 425 total deaths, 103 CVD deaths, 169 cancer deaths and 153 due to other-causes deaths occurred. Hazard ratios (HRs) [95% confidence interval (CI)] of CVD mortality were 1.52 (1.02-2.89) (P-trend = 0.034) and 2.23 (1.32-3.78) (P-trend = 0.002) for the 3rd tertile of total legumes and dry beans consumption, respectively, compared with the 1st tertile. When comparing extreme tertiles, higher total legumes and lentils consumption was associated with 49% (HR: 0.51; 95% CI: 0.31-0.84; P-trend = 0.009) and 37% (HR: 0.63; 95% CI: 0.40-0.98; P-trend = 0.049) lower risk of cancer mortality. Similar associations were observed for CVD death in males and for cancer death in males, obese and diabetic participants. CONCLUSIONS: These findings support the benefits of legumes consumption for cancer mortality prevention which may be counterbalanced by their higher risk for CVD mortality., Centro de Investigacion Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN) is an initiative of the Instituto de Salud Carlos III (ISCIII) of Spain which is supported by FEDER funds (CB06/03). Supported by the official funding agency for biomedical research of the Spanish government, ISCIII, through grants provided to research networks specifically developed for the trial (RTIC G03/140 and RD 06/0045 through CIBEROBN, and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigacion Sanitaria eFondo Europeo de Desarrollo Regional (PI04e2239, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, and PI11/02505; PI13/00462), Ministerio de Ciencia e Innovacion (AGL- 2009e13906-C02 and AGL2010e22319-C03), Fundacion Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVA-COMP2010e181, GVACOMP2011e151, CS2010- AP-111, and CS2011-AP-042), and the Navarra Regional Government (27/2011). The Fundacion Patrimonio Comunal Olivarero and Hojiblanca SA (Malaga, Spain), California Walnut Commission (Sac- ramento, CA), Borges SA (Reus, Spain), and Morella Nuts SA (Reus, Spain) donated the olive oil, walnuts, almonds, and hazelnuts, respectively, used in the study
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial

  • Martínez-González, Miguel Ángel, 1957-
  • Hernáez, Álvaro
  • Castañer, Olga
  • Salas Salvadó, Jordi
Background: Several large observational prospective studies have reported a protection by the traditional Mediterranean diet against type 2 diabetes, but none of them used yearly repeated measures of dietary intake. Repeated measurements of dietary intake are able to improve subject classification and to increase the quality of the assessed relationships in nutritional epidemiology. Beyond observational studies, randomized trials provide stronger causal evidence. In the context of a randomized trial of primary cardiovascular prevention, we assessed type 2 diabetes incidence according to yearly repeated measures of compliance with a nutritional intervention based on the traditional Mediterranean diet. Methods: PREDIMED (''PREvención con DIeta MEDiterránea'') was a Spanish trial including 7447 men and women at high cardiovascular risk. We assessed 3541 participants initially free of diabetes and originally randomized to 1 of 3 diets: low-fat diet (n = 1147, control group), Mediterranean diet supplemented with extra virgin olive (n = 1154) or Mediterranean diet supplemented with mixed nuts (n = 1240). As exposure we used actual adherence to Mediterranean diet (cumulative average), yearly assessed with the Mediterranean Diet Adherence Screener (scoring 0 to 14 points), and repeated up to 8 times (baseline and 7 consecutive follow-up years). This score was categorized into four groups: < 8, 8-< 10, 10- < 12, and 12-14 points. The outcome was new-onset type 2 diabetes. Results: Multivariable-adjusted hazard ratios from time-varying Cox models were 0.80 (95% confidence interval, 0.70-0.92) per + 2 points in Mediterranean Diet Adherence Screener (linear trend p = .001), and 0.46 (0.25-0.83) for the highest (12-14 points) versus the lowest (< 8) adherence. This inverse association was maintained after additionally adjusting for the randomized arm. Age- and sex-adjusted analysis of a validated plasma metabolomic signature of the Mediterranean Diet Adherence Screener (constituted of 67 metabolites) in a subset of 889 participants also supported these results. Conclusions: Dietary intervention trials should quantify actual dietary adherence throughout the trial period to enhance the benefits and to assist results interpretation. A rapid dietary assessment tool, yearly repeated as a screener, was able to capture a strong inverse linear relationship between Mediterranean diet and type 2 diabetes. Trial registration ISRCTN35739639., Primary Funding Source Instituto de Salud Carlos III. The PREDIMED trial was supported by Instituto de Salud Carlos III (ISCIII), the official funding agency for biomedical research of the Spanish government, through grants provided to research networks specifically developed for the trial (RTIC G03/140, to Ramón Estruch during 2003–2005; RTIC RD 06/0045, to Miguel A. Martínez-González during 2006–2013 and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBEROBN]), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462, and JR17/00022), Ministerio de Ciencia e Innovación (AGL-2009–13906-C02, AGL2010- 22319-C03, AGL2011-23430, and SAF2016–80532-R), Fundación Mapfre 2010 (no role in the design, implementation, analysis or interpretation of the data), Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (PROMETEO 17/2017, and PROMETEO 21/2021), Fundació La Marató-TV3 (grants 294/C/2015 and 538/U/2016 (no role in the design, implementation, analysis or interpretation of the data)), Agencia Canaria de Investigación, Innovación y Sociedad de la Información-EU FEDER (PI 2007/050 and CS2011-AP-042), and Regional Government of Navarra (P27/2011). The metabolomic study was supported by research grant NIDDK-R01DK 102896 from the National Institutes of Health. Donations of olive oil, walnuts, almonds, and hazelnuts were made respectively by the Fundación Patrimonio Comunal Olivarero and Hojiblanca (Malaga, Spain), California Walnut Commission (Sacramento, California), Borges (Reus, Spain), and Morella Nuts (Reus, Spain). Prof. Jordi Salas-Salvadó is partially supported by ICREA, under the ICREA Academia programme.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Yearly attained adherence to Mediterranean diet and incidence of diabetes in a large randomized trial

  • Martínez-González, Miguel Ángel, 1957-
  • Montero, Pedro
  • Ruiz-Canela, Miguel
  • Toledo, Estefanía
  • Estruch Riba, Ramon
  • Gómez-Gracia, Enrique
  • Li, Jun
  • Ros Rahola, Emilio
  • Arós, Fernando
  • Hernáez, Álvaro
  • Corella Piquer, Dolores
  • Fiol, Miquel
  • Lapetra, José
  • Serra Majem, Lluís
  • Pintó Sala, Xavier
  • Cofán Pujol, Montserrat
  • Sorlí, José V.
  • Babio, Nancy
  • Márquez-Sandoval, Yolanda F.
  • Castañer, Olga
  • Salas Salvadó, Jordi
Background Several large observational prospective studies have reported a protection by the traditional Mediterranean diet against type 2 diabetes, but none of them used yearly repeated measures of dietary intake. Repeated measurements of dietary intake are able to improve subject classification and to increase the quality of the assessed relationships in nutritional epidemiology. Beyond observational studies, randomized trials provide stronger causal evidence. In the context of a randomized trial of primary cardiovascular prevention, we assessed type 2 diabetes incidence according to yearly repeated measures of compliance with a nutritional intervention based on the traditional Mediterranean diet. Methods PREDIMED (‘‘PREvención con DIeta MEDiterránea’’) was a Spanish trial including 7447 men and women at high cardiovascular risk. We assessed 3541 participants initially free of diabetes and originally randomized to 1 of 3 diets: low-fat diet (n = 1147, control group), Mediterranean diet supplemented with extra virgin olive (n = 1154) or Mediterranean diet supplemented with mixed nuts (n = 1240). As exposure we used actual adherence to Mediterranean diet (cumulative average), yearly assessed with the Mediterranean Diet Adherence Screener (scoring 0 to 14 points), and repeated up to 8 times (baseline and 7 consecutive follow-up years). This score was categorized into four groups: < 8, 8–< 10, 10– < 12, and 12–14 points. The outcome was new-onset type 2 diabetes. Results Multivariable-adjusted hazard ratios from time-varying Cox models were 0.80 (95% confidence interval, 0.70–0.92) per + 2 points in Mediterranean Diet Adherence Screener (linear trend p = .001), and 0.46 (0.25–0.83) for the highest (12–14 points) versus the lowest (< 8) adherence. This inverse association was maintained after additionally adjusting for the randomized arm. Age- and sex-adjusted analysis of a validated plasma metabolomic signature of the Mediterranean Diet Adherence Screener (constituted of 67 metabolites) in a subset of 889 participants also supported these results. Conclusions Dietary intervention trials should quantify actual dietary adherence throughout the trial period to enhance the benefits and to assist results interpretation. A rapid dietary assessment tool, yearly repeated as a screener, was able to capture a strong inverse linear relationship between Mediterranean diet and type 2 diabetes., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Metabolites related to purine catabolism and risk of type 2 diabetes incidence; modifying effects of the TCF7L2-rs7903146 polymorphism

  • Papandreou, Christopher
  • Li, Jun
  • Liang, Liming
  • Bulló, Mònica
  • Zheng, Yan
  • Ruiz-Canela, Miguel
  • Yu, Edward
  • Guasch-Ferré, Marta
  • Razquin, Cristina
  • Clish, Clary B.
  • Corella, Dolores
  • Estruch, Ramón
  • Ros, Emilio
  • Fitó Colomer, Montserrat
  • Arós, Fernando
  • Serra-Majem, Luis
  • Rosique-Esteban, Nuria
  • Martínez-González, Miguel Ángel, 1957-
  • Hu, Frank B.
  • Salas-Salvadó, Jordi
Studies examining associations between purine metabolites and type 2 diabetes (T2D) are limited. We prospectively examined associations between plasma levels of purine metabolites with T2D risk and the modifying effects of transcription factor-7-like-2 (TCF7L2) rs7903146 polymorphism on these associations. This is a case-cohort design study within the PREDIMED study, with 251 incident T2D cases and a random sample of 694 participants (641 non-cases and 53 overlapping cases) without T2D at baseline (median follow-up: 3.8 years). Metabolites were semi-quantitatively profiled with LC-MS/MS. Cox regression analysis revealed that high plasma allantoin levels, including allantoin-to-uric acid ratio and high xanthine-to-hypoxanthine ratio were inversely and positively associated with T2D risk, respectively, independently of classical risk factors. Elevated plasma xanthine and inosine levels were associated with a higher T2D risk in homozygous carriers of the TCF7L2-rs7903146 T-allele. The potential mechanisms linking the aforementioned purine metabolites and T2D risk must be also further investigated., This study was supported by research grant R01-DK-102896 from the National Institutes of Health. The Prevención con DietaMediterránea (PREDIMED) trial was supported by the official funding agency for biomedical research of the Spanish government, the Instituto de Salud Carlos III, through grants provided to research networks specifically developed for the trial [grant RTIC G03/140 (to Ramón Estruch); grant RTIC RD 06/0045 (to Miguel A. Martínez-González)] and through the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición and by grants from Centro Nacional de Investigaciones Cardiovasculares (grant CNIC 06/2007), the Fondo de Investigación Sanitaria Fondo Europeo de Desarrollo Regional (grants PI04–2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, and PI13/00462), the Ministerio de Ciencia e Innovación (grants AGL-2009–13906-C02 and AGL2010–22319-C03), the Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (grant PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (grants ACOMP06109, GVA-COMP2010–181, GVACOMP2011–151, CS2010-AP-111, and CS2011-AP-042), and the Regional Government of Navarra (grant P27/2011). Genotyping of the TCF7L2-rs7903146 polymorphism was supported by PROMETEO17/2017 from the Generalitat Valenciana, and 538/U/2016 from Fundacio la Marato-TV3. Dr. Christopher Papandreou was supported by a postdoctoral fellowship granted by the Autonomous Government of Catalonia (PERIS 2016-2020 INCORPORACIÓ DE CIENTÍFICAS I TECNÒLEGS, SLT002/0016/00428). Dr Marta Guasch-Ferré was supported by a postdoctoral fellowship granted by the Lilly Foundation European Association of Diabetes (EASD) through the Institut d’Investigacions Sanitàries Pere i Virgili (IISPV), Tarragona, Spain. The authors are indebted to George A. Fragkiadakis (Department of Nutrition & Dietetics, Technological Education Institute of Crete, Greece) for his intellectual contributions to this manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The PREDIMED trial, Mediterranean diet and health outcomes: How strong is the evidence?

  • Guasch-Ferré, Marta
  • Salas-Salvadó, Jordi
  • Ros, Emilio
  • Estruch, Ramón
  • Corella, Dolores
  • Fitó Colomer, Montserrat
  • Martínez-González, Miguel Ángel, 1957-
  • PREDIMED investigators
AIMS: To address potential controversies on the health benefits of the Mediterranean diet (MedDiet) after PREDIMED, a randomized trial of MedDiet for primary cardiovascular prevention. We have focused on: a) the PREDIMED study design, b) analysis of PREDIMED data and c) interpretation of its results. DATA SYNTHESIS: Regarding the design of the trial, its early termination and between-group differences in the intensity of the intervention are potential causes of concern. The planned duration was 6 years but the trial was prematurely stopped when an interim analysis at 4.8-year provided sufficient evidence of benefit for the two MedDiets. In the MedDiet groups supplemented with extra-virgin olive oil or mixed-nuts, the primary composite endpoint (myocardial infarction, stroke, or cardiovascular death) was reduced by 30% and 28% respectively, as compared with the control group. Final results did not change after taking into account the different intensity of educational efforts during the trial. Other potential doubts related to data analysis (e.g., intention to treat versus a per-protocol approach, and consequences of dropouts) should not be causes of concern. Finally, we addressed alternative interpretations of the effect on all-cause mortality. The protocol-defined primary endpoint was a composite cardiovascular endpoint, not all-cause mortality. To analyze total mortality, we would have needed a much larger sample size and longer follow-up. Therefore, the PREDIMED results cannot be used to draw firm conclusions on MedDiets and all-cause mortality. CONCLUSIONS: The PREDIMED study was designed to overcome three major problems of previous nutritional research: a) residual confounding, addressed by using a randomized design; b) single-nutrient approaches, by randomizing an overall dietary pattern; and c) the limitations of assessing only intermediate risk markers, by using hard clinical end-points., Supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research net-works specifically developed for the trial (RTIC G03/140(2003e2005), to Dr. Estruch; RTIC RD 06/0045(2006e2013), to Dr. Martínez González and through Centrode Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBERobn]), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC06/2007), Fondo de Investigación Sanitaria de Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100,PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407,PI10/02658, PI11/01647, and P11/02505), Ministerio de Ciencia e Innovación (AGL-2009-1390 6-C02 and AGL2010-22319-C03), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Divisionof the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109,GVACOMP2010-181, GVACOMP2011-151, CS2010-AP-111 and CS2011 AP-042), and Regional Government of Navarra(P27/2011). Dr. Estruch reports serving on the board of and receiving lecture fees from the Research Foundationon Wine and Nutrition (FIVIN); serving on the boards of the Beer and Health Foundation and the European Foun-dation for Alcohol Research (ERAB); receiving lecture fees from Cerveceros de España and Sanofi Aventis; andreceiving grant support through his institution fromNovartis. Dr. Ros reports serving on the board of andreceiving travel support, as well as grant support throughhis institution, from the California Walnut Commission; serving on the board of the Flora Foundation (Unilever);serving on the board of and receiving lecture fees from Roche; serving on the board of and receiving grant support through his institution from Amgen; receiving consulting fees from Damm and Abbott Laboratories; receiving consulting fees and lecture fees, as well as grant support through his institution, from Merck; receiving lecture fees from Danone, Pace, AstraZeneca, and Rottapharm; receiving lecture fees and payment for the development of educational presentations, as well as grant support through his institution, from Ferrer; receiving payment for the devel-opment of educational presentations from Recordati; and receiving grant support through his institution from Sanofi-Aventis, Takeda, Daiichi Sankyo, Nutrexpa, Feiraco, Unilever,and Karo Bio. Dr. Salas-Salvadó reports serving on the boardof and receiving grant support through his institution fromthe International Nut and Dried Fruit Council; receiving consulting fees from Danone; and receiving grant support through his institution from Eroski and Nestlé. No other potential conflict of interest relevant to this article was reported.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Quality of dietary fat intake and body weight and obesity in a mediterranean population: secondary analyses within the PREDIMED trial

  • Beulen, Yvette
  • Martínez-González, Miguel Ángel, 1957-
  • van de Rest, Ondine
  • Salas-Salvadó, Jordi
  • Sorlí, José Vicente
  • Gómez-Gracia, Enrique
  • Fiol, Miquel
  • Estruch, Ramón
  • Santos-Lozano, José
  • Schröder, Helmut, 1958-
  • Alonso-Gómez, Ángel
  • Serra-Majem, Luis
  • Pinto, Xavier
  • Ros, Emilio
  • Becerra-Tomás, Nerea
  • González, José I.
  • Fitó Colomer, Montserrat
  • Martínez, José Alfredo
  • Gea, Alfredo
A moderately high-fat Mediterranean diet does not promote weight gain. This study aimed to investigate the association between dietary intake of specific types of fat and obesity and body weight. A prospective cohort study was performed using data of 6942 participants in the PREDIMED trial, with yearly repeated validated food-frequency questionnaires, and anthropometric outcomes (median follow-up: 4.8 years). The effects of replacing dietary fat subtypes for one another, proteins or carbohydrates were estimated using generalized estimating equations substitution models. Replacement of 5% energy from saturated fatty acids (SFA) with monounsaturated fatty acids (MUFA) or polyunsaturated fatty acids (PUFA) resulted in weight changes of -0.38 kg (95% Confidece Iinterval (CI): -0.69, -0.07), and -0.51 kg (95% CI: -0.81, -0.20), respectively. Replacing proteins with MUFA or PUFA decreased the odds of becoming obese. Estimates for the daily substitution of one portion of red meat with white meat, oily fish or white fish showed weight changes up to -0.87 kg. Increasing the intake of unsaturated fatty acids at the expense of SFA, proteins, and carbohydrates showed beneficial effects on body weight and obesity. It may therefore be desirable to encourage high-quality fat diets like the Mediterranean diet instead of restricting total fat intake., The PREDIMED trial (www.predimed.es) was supported by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Health, through grants provided to research networks specifically developed for the trial, namely, RTIC G03/140 (Coordinator: R. Estruch, M.D., Ph.D., during 2003-2005) and RTIC RD 06/0045 (Coordinator: M.A. Martínez-González, M.D., Ph.D., during 2006-2013). We also acknowledge CIBERobn (an Initiative of ISCIII), the grants from Centro Nacional de Investigaciones Cardiovasculares CNIC 06/2007, Fondo de Investigación Sanitaria—Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505), Ministerio de Ciencia e Innovación (AGL-2009-13906-C02, AGL2010-22319-C03), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVACOMP2010-181, GVACOMP2011-151, CS2010-AP-111, CS2011-AP-042, and PROMETEO17/2017), and Regional Government of Navarra (P27/2011).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Lipid metabolic networks, Mediterranean diet and cardiovascular disease in the PREDIMED trial

  • Wang, Dong D.
  • Fitó Colomer, Montserrat
  • Hu, Frank B.
BACKGROUND: Perturbed lipid metabolic pathways may play important roles in the development of cardiovascular disease (CVD). However, existing epidemiological studies have focused more on discovering individual lipid metabolites for CVD risk prediction rather than assessing metabolic pathways. METHODS: This study included a subcohort of 787 participants and all 230 incident CVD cases from the PREDIMED trial. Applying a network-based analytical method, we identified lipid subnetworks and clusters from a global network of 200 lipid metabolites and linked these subnetworks/clusters to CVD risk. RESULTS: Lipid metabolites with more double bonds clustered within one subnetwork, whereas lipid metabolites with fewer double bonds clustered within other subnetworks. We identified 10 lipid clusters that were divergently associated with CVD risk. The hazard ratios [HRs, 95% confidence interval (CI)] of CVD per a 1-standard deviation (SD) increment in cluster score were 1.39 (1.17-1.66) for the hydroxylated phosphatidylcholine (HPC) cluster and 1.24 (1.11-1.37) for a cluster that included diglycerides and a monoglyceride with stearic acyl chain. Every 1-SD increase in the score of cluster that included highly unsaturated phospholipids and cholesterol esters was associated with an HR for CVD of 0.81 (95% CI, 0.67-0.98). Despite a suggestion that MedDiet modified the association between a subnetwork that included most lipids with a high degree of unsaturation and CVD, changes in lipid subnetworks/clusters during the first-year follow-up were not significantly different between intervention groups. CONCLUSIONS: The degree of unsaturation was a major determinant of the architecture of lipid metabolic network. Lipid clusters that strongly predicted CVD risk, such as the HPC cluster, warrant further functional investigations., This work was supported by a research grant from the National Institutes of Health [R01 HL118264]. The Prevención con Dieta Mediterránea (PREDIMED) trial was supported by the official funding agency for biomedical research of the Spanish government, the Instituto de Salud Carlos III, through grants provided to research networks specifically developed for the trial (RTIC G03/140 to R.E. and RTIC RD 06/0045 to Dr. Miguel A. Martínez-González) and through the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición and by grants from: the Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007); the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04–2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462); the Ministerio de Ciencia e Innovación (AGL-2009–13906-C02 and AGL2010–22319-C03); the Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007); the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVACOMP2010–181, GVACOMP2011–151, CS2010-AP-111, and CS2011-AP-042); and the Regional Government of Navarra (P27/2011). Dr. Dong D Wang was supported by a postdoctoral fellowship granted by the American Heart Association (16POST31100031)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Arginine catabolism metabolites and atrial fibrillation or heart failure risk: 2 case-control studies within the Prevención con Dieta Mediterránea (PREDIMED) trial

  • Goni, Leticia
  • Fitó Colomer, Montserrat
  • Ruiz-Canela, Miguel
Background Arginine-derived metabolites are involved in oxidative and inflammatory processes related to endothelial functions and cardiovascular risks. Objectives We prospectively examined the associations of arginine catabolism metabolites with the risks of atrial fibrillation (AF) or heart failure (HF), and evaluated the potential modifications of these associations through Mediterranean diet (MedDiet) interventions in a large, primary-prevention trial. Methods Two nested, matched, case-control studies were designed within the Prevención con Dieta Mediterránea (PREDIMED) trial. We selected 509 incident cases and 547 matched controls for the AF case-control study and 326 cases and 402 matched controls for the HF case-control study using incidence density sampling. Fasting blood samples were collected at baseline and arginine catabolism metabolites were measured using LC-tandem MS. Multivariable conditional logistic regression models were applied to test the associations between the metabolites and incident AF or HF. Interactions between metabolites and intervention groups (MedDiet groups compared with control group) were analyzed with the likelihood ratio test. Results Inverse association with incident AF was observed for arginine (OR per 1 SD, 0.83; 95% CI: 0.73–0.94), whereas a positive association was found for N1-acetylspermidine (OR for Q4 compared with Q1 1.58; 95% CI: 1.13–2.25). For HF, inverse associations were found for arginine (OR per 1 SD, 0.82; 95% CI: 0.69–0.97) and homoarginine (OR per 1 SD, 0.81; 95% CI: 0.68–0.96), and positive associations were found for the asymmetric dimethylarginine (ADMA) and symmetric dimethlyarginine (SDMA) ratio (OR per 1 SD, 1.19; 95% CI: 1.02–1.41), N1-acetylspermidine (OR per 1 SD, 1.34; 95% CI: 1.12–1.60), and diacetylspermine (OR per 1 SD, 1.20; 95% CI: 1.02–1.41). In the stratified analysis according to the dietary intervention, the lower HF risk associated with arginine was restricted to participants in the MedDiet groups (P-interaction = 0.044). Conclusions Our results suggest that arginine catabolism metabolites could be involved in AF and HF. Interventions with the MedDiet may contribute to strengthen the inverse association between arginine and the risk of HF. This trial was registered at controlled-trials.com as ISRCTN35739639., Supported by National Heart, Lung, and Blood Institute research grant R01HL118264 (to FBH). The PREDIMED (Prevención con Dieta Mediterránea) trial was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III, through grants provided to research networks specifically developed for the trial: RTIC G03/140 (to RE) during 2003–2005 and RTIC RD 06/0045 (to MAM-G) during 2006–2013 and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (to MAM-G); Centro Nacional de Investigaciones Cardiovasculares grant CNIC 06/2007; Fondo de Investigación Sanitaria—Fondo Europeo de Desarrollo Regional grants PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462, and JR17/00022; Ministerio de Ciencia e Innovación grants AGL-2009-13906- C02, AGL2010-22319-C03, and SAF2016-80532-R; Fundación Mapfre 2010 (which had no role in the design, implementation, analysis, or interpretation of the data); Consejería de Salud de la Junta de Andalucía grant PI0105/2007; Public Health Division of the Department of Health of the Autonomous Government of Catalonia; Generalitat Valenciana grants ACOMP06109, GVA-COMP2010-181, GVACOMP2011-151, CS2010-AP111, PROMETEO 17/2017, and CS2011-AP-042; Fundació La MaratóTV3 (which had no role in the design, implementation, analysis, or interpretation of the data) grants 294/C/2015 and 538/U/2016; and Regional Government of Navarra grant P27/2011.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Circulating amino acids and risk of peripheral artery disease in the PREDIMED Trial

  • Razquin, Cristina
  • Fitó Colomer, Montserrat
  • Martínez-González, Miguel Ángel, 1957-
Effective prevention and risk prediction are important for peripheral artery disease (PAD) due to its poor prognosis and the huge disease burden it produces. Circulating amino acids (AA) and their metabolites may serve as biomarkers of PAD risk, but they have been scarcely investigated. The objective was to prospectively analyze the associations of baseline levels of plasma AA (and their pathways) with subsequent risk of PAD and the potential effect modification by a nutritional intervention with the Mediterranean diet (MedDiet). A matched case-control study was nested in the PREDIMED trial, in which participants were randomized to three arms: MedDiet with tree nut supplementation group, MedDiet with extra-virgin olive oil (EVOO) supplementation group or control group (low-fat diet). One hundred and sixty-seven PAD cases were matched with 250 controls. Plasma AA was measured with liquid chromatography/mass spectrometry at the Broad Institute. Baseline tryptophan, serine and threonine were inversely associated with PAD (ORfor 1 SD increase = 0.78 (0.61–0.99); 0.67 (0.51–0.86) and 0.75 (0.59–0.95), respectively) in a multivariable-adjusted conditional logistic regression model. The kynurenine/tryptophan ratio was directly associated with PAD (ORfor 1 SD increase = 1.50 (1.14–1.98)). The nutritional intervention with the MedDiet+nuts modified the association between threonine and PAD (p-value interaction = 0.018) compared with the control group. However, subjects allocated to the MedDiet+EVOO group were protected against PAD independently of baseline threonine. Plasma tryptophan, kynurenine/tryptophan ratio, serine and threonine might serve as early biomarkers of future PAD in subjects at a high risk of cardiovascular disease. The MedDiet supplemented with EVOO exerted a protective effect, regardless of baseline levels of threonine., This work was supported by the National Institutes of Health research grant R01HL118264 (1R01HL118264-01/2R01HL118264-05/2R01HL118264-09). The PREDIMED trial was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140 to Ramón Estruch during 2003–2005; RTIC RD 06/0045 to Miguel A. Martínez-González during 2006–2013 and through the Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBEROBN]), and by grants from the Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (PI04–2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462 and JR17/00022), the Ministerio de Ciencia e Innovación (AGL-2009–13906-C02, AGL2010–22319-C03 and SAF2016–80532-R), the Fundación Mapfre 2010 (no role in the design, implementation, analysis or interpretation of the data), the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVA-COMP2010–181, GVACOMP2011–151, CS2010-AP-111, PROMETEO 17/2017 and CS2011-AP-042), the Fundació La Marató-TV3 (grants 294/C/2015 and 538/U/2016 (no role in the design, implementation, analysis or interpretation of the data)) and the Regional Government of Navarra (P27/2011). Marta Guasch-Ferré was supported by the American Diabetes Association, grant #1-18-PMF-029. Jordi Salas-Salvadó was partially supported by ICREA under the ICREA Academia programme. Wittenbecher was supported by the SciLifeLab & Wallenberg Data Driven Life Science Program (grant: KAW 2020.0239). Marta Guasch-Ferré was supported by NNF18CC0034900.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Simple sugar intake and cancer incidence, cancer mortality and all-cause mortality: a cohort study from the PREDIMED trial

  • Laguna, Juan Carlos
  • Fitó Colomer, Montserrat
  • Ros, Emilio
Objective: To examine associations between intake of simple sugars and cancer incidence, cancer mortality, and total mortality in a prospective cohort study based on the PREDIMED trial conducted from 2003 to 2010. Methods: Participants were older individuals at high cardiovascular risk. Exposures were total sugar, glucose and fructose from solid or liquid sources, and fructose from fruit and 100% fruit juice. Cancer incidence was the primary outcome; cancer mortality and all-cause mortality were secondary outcomes. Multivariable-adjusted, time-dependent Cox proportional hazard models were used. Results: Of 7447 individuals enrolled, 7056 (94.7%) were included (57.6% women, aged 67.0 ± 6.2 years). 534 incident cancers with 152 cancer deaths and 409 all-cause deaths were recorded after a median follow-up of 6 years. Intake of simple sugars in solid form was unrelated to outcomes. Higher cancer incidence was found per 5 g/day increase in intake of liquid sugars, with multivariable-adjusted HR of 1.08 (95% CI, 1.03-1.13) for total liquid sugar, 1.19 (95% CI, 1.07-1.31) for liquid glucose, 1.14 (95% CI, 1.05-1.23) for liquid fructose, and 1.39 (95% CI, 1.10-1.74) for fructose from fruit juice. Cancer and all-cause mortality increased to a similar extent with intake of all sugars in liquid form. In categorical models, cancer risk was dose-related for all liquid sugars. Conclusions: Simple sugar intake in drinks and fruit juice was associated with an increased risk of overall cancer incidence and mortality and all-cause mortality. This suggests that sugary beverages are a modifiable risk factor for cancer and all-cause mortality., This work was supported by the official Spanish Institutions for funding scientific biomedical research, CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) and Instituto de Salud Carlos III (ISCIII), through the Fondo de Investigaciones Sanitarias (FIS), which is co-funded by the European Regional Development Fund (FIS projects, PI04-2239, PI05/2368, PI05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, and P11/02505), Spanish Ministry of Economy, Industry and Competitiveness (SAF2017-82369-R, AGL-2009-13906-C02, and AGL2010-22319-C03), Generalitat de Catalunya (2017 SGR 38), Generalitat Valenciana (GV2016-141), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), and Regional Government of Navarra (P27/2011). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Food biodiversity and mortality in older Mediterranean adults with high cardiovascular risk

  • Shyam, Sangeetha
  • Babio, Nancy
  • Paz-Graniel, Indira
  • Martínez-González, Miguel Ángel, 1957-
  • Sorlí, José Vicente
  • Estruch, Ramón
  • Ros, Emilio
  • Tojal Sierra, Lucas
  • Gómez-Gracia, Enrique
  • Fiol, Miquel
  • Lapetra, José
  • Serra Majem, Lluís
  • Riera-Mestre, Antoni
  • Toledo, Estefania
  • Ramirez-Sabio, Judith B
  • Castañer, Olga
  • Lamuela Raventós, Rosa Ma.
  • Margara Escudero, Hernando J.
  • Fitó Colomer, Montserrat
  • Salas Salvadó, Jordi
The food system is a key determinant of population and planetary health. As the "one planet, one health" approach gains momentum, evaluating "food biodiversity" and its association with mortality in high-risks populations is increasingly important. Hence, we evaluated the associations of food biodiversity with all-cause and cause-specific mortality in a Spanish cohort of older adults at high cardiovascular risks. Food biodiversity was defined using dietary species richness (DSR), the count of unique plants and animal species consumed by an individual. DSR was cumulatively calculated over the PREDIMED study follow-up, using yearly food frequency questionnaire data. The association of food biodiversity with all-cause and cause-specific mortality was assessed using Cox regression, while controlling for confounders. We analyzed data from 7210 participants (58 % women), with a median age of 67 years. DSR in the cohort ranged between 16 and 57 (median: 48). Over a median follow-up of 6 years, 425 deaths were recorded (103 deaths from cardiovascular diseases (CVD), 169 cancer deaths, and 153 deaths due to other-causes). DSR was only moderately correlated with adherence to the Mediterranean diet. On average, when fully adjusted, every additional species over the follow-up period was associated with a Hazard Ratio (HR (95 % Confidence Interval) of 0.91(0.90,0.93) for all-cause mortality, 0.93(0.90,0.96) for CVD mortality, 0.92 (0.89,0.94) for cancer deaths, and a 0.91(0.89,0.94) for deaths from other causes. Dietary recommendations to improve food biodiversity may increase longevity., Supported by Instituto de Salud Carlos III, Spanish Ministry of Health, through grants provided to research networks specifically developed for the study (RTIC G03/140, to Dr. Estruch, and RTIC RD 06/0045, to Dr. Martínez-González); Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición; and grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, and P11/02505), Ministerio de Ciencia e Innovación (AGL-2009-13906-C02 and AGL2010-22319-C03), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVACOMP2010-181, GVACOMP2011-151, CS2010-AP-111, and CS2011-AP-042), and Regional Government of Navarra (P27/2011).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Alteraciones mayores del electrocardiograma y riesgo cardiovascular en la población mediterránea de medio y alto riesgo

  • Pou Bordoy, Joan
  • Leiva, Alfonso
  • Albendín Ariza, Maria José
  • Elosua Llanos, Roberto
  • Rigo Carratalà, Fernando
  • Romaguera Bosch, Dora
  • Salas Salvadó, Jordi
  • Babio, Nancy
  • Martínez-González, Miguel Ángel, 1957-
  • Toledo, Estefania
  • Fitó Colomer, Montserrat
  • Arós, Fernando
  • Estruch, Ramón
  • Fiol, Miquel
Introducción: Las alteraciones mayores del electrocardiograma (AMECG) son frecuentes en personas de mediana y avanzada edad, y podrían ser un factor importante en la predicción de eventos cardiovasculares (ECV). Objetivo: Analizar la asociación entre AMECG (clasificación de Minnesota) y ECV independientemente de los factores de riesgo cardiovascular (FRCV) clásicos y valorar si mejoran la predicción de la función de riesgo FRESCO-Función de Riesgo Española de Acontecimientos Coronarios. Método: Se incluyeron 1.752 participantes del estudio PREDIMED entre 55 y 80 años con RCV medio o alto, con una media de seguimiento de 5,1 años. Durante el periodo de seguimiento se ha estimado la incidencia acumulada de ECV por sexo y presencia de AMECG, y analizado la asociación entre AMECG y ECV mediante regresión multivariante de Cox ajustadas por grupo de aleatorización y RCV (FRESCO). Para analizar la mejora en la predicción se calcularon los índices C de Harrel's, Nam d’Agostino, Net Reclassification Improvement e Integrated Discrimination Improvement. Resultados: Al inicio del estudio, un 25% de los participantes presentaron AMECG. Durante el seguimiento aparecieron 112 ECV (16 muertes cardiovasculares, 15 infartos agudo de miocardio, 38 anginas, 43 accidentes cerebrovasculares). Las AEMCG se asociaron a una mayor probabilidad de sufrir un ECV. En varones, las principales AMECG asociadas a la aparición de ECV fueron los criterios de hipertrofia de ventrículo izquierdo (HVE) con inversión de onda T (HR: 17,88; IC 95%: 5,51-58,03; p valor < 0,001) y el alargamiento de QT (HR: 2,41; IC 95%: 1,38-4,21; p valor = 0,002), y en mujeres la fibrilación auricular (HR: 5,7; IC 95%: 1,76-18,72; p valor = 0,006) y el descenso del ST (HR: 3,24; IC 95%: 1,36-7,71; p valor < 0,001). No se observó mejoría significativa en la capacidad predictiva de FRESCO al introducir las AMECG. Conclusiones: Las AMECG se asocian de manera independiente con los ECV, por lo que deben ser consideradas durante el curso del proceso clínico. Sin embargo, no ofrece una mejora adicional en la predicción del riesgo cardiovascular a la proporcionada por los factores de riesgo clásicos., Instituto de Salud Carlos III. El ensayo PREDIMED contó con el apoyo del Instituto de Salud Carlos III (ISCIII), la agencia oficial de financiamiento para la investigación biomédica del gobierno español, a través de subvenciones otorgadas a redes de investigación específicamente desarrolladas para el ensayo (RTIC G03/140, a Ramón Estruch durante 2003-2005; RTIC RD 06/0045, a Miguel A. Martínez-González durante 2006-2013 y a través del Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición [CIBEROBN]), y mediante subvenciones del Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462 y JR17/00022) financiadas por el Ministerio de Economía y Competitividad, Instituto Carlos III y también contó con el apoyo de fondos proporcionados por la Red de Atención Primaria y promoción de la Salud (RICAPPS) RD21/0016/0009, cofinanciado con fondos de Next Generation EU, que financian las actuaciones del Mecanismo de Recuperación y Resiliencia (MRR), Ministerio de Ciencia e Innovación (AGL-2009-13906-C02, AGL2010-22319-C03, AGL2011-23430 y SAF2016-80532-R), Fundación Mapfre 2010 (sin participación en el diseño, implementación, análisis o interpretación de los datos), Consejería de Salud de la Junta de Andalucía (PI0105/2007), División de Salud Pública del Departamento de Salud de la Generalitat de Cataluña, Generalitat Valenciana (PROMETEO 17/2017 y PROMETEO 21/2021), Fundació La Marató-TV3 (subvenciones 294/C/2015 y 538/U/2016, sin participación en el diseño, implementación, análisis o interpretación de los datos)), Agencia Canaria de Investigación, Innovación y Sociedad de la Información-EU FEDER (PI 2007/050 y CS2011-AP-042), y Gobierno Regional de Navarra (P27/2011). El estudio metabolómico recibió el respaldo de la subvención de investigación NIDDK-R01DK 102896. Las donaciones de aceite de oliva, nueces, almendras y avellanas fueron realizadas, respectivamente, por la Fundación Patrimonio Comunal Olivarero y Hojiblanca (Málaga, España), California Walnut Commission (Sacramento, California), Borges (Reus, España) y Morella Nuts (Reus, España). El Prof. Jordi Salas-Salvadó cuenta con el apoyo parcial de ICREA, en el marco del programa ICREA Academia.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Egg consumption and cardiovascular disease according to diabetic status: The PREDIMED study

  • Díez-Espino, J.
  • Basterra-Gortari, F. Javier
  • Salas-Salvadó, Jordi
  • Buil-Cosiales, Pilar
  • Corella, Dolores
  • Schröder, Helmut, 1958-
  • Estruch, Ramón
  • Ros, Emilio
  • Gómez-Gracia, Enrique
  • Arós, Fernando
  • Fiol, Miquel
  • Lapetra, José
  • Serra-Majem, Luis
  • Pintó Sala, Xavier
  • Babio, Nancy
  • Quiles, Laura
  • Fitó Colomer, Montserrat
  • Martí, Amelia
  • Toledo, Estefania
  • PREDIMED investigators
BACKGROUND: Eggs are a major source of dietary cholesterol and their consumption has been sometimes discouraged. A relationship between egg consumption and the incidence of cardiovascular disease (CVD) has been suggested to be present exclusively among patients with type2 diabetes. AIMS: To assess the association between egg consumption and CVD in a large Mediterranean cohort where approximately 50% of participants had type 2 diabetes. METHODS: We prospectively followed 7216 participants (55-80 years old) at high cardiovascular risk from the PREDIMED (PREvención con DIeta MEDiterránea) study for a mean of 5.8 years. All participants were initially free of CVD. Yearly repeated measurements of dietary information with a validated 137-item food-frequency questionnaire were used to assess egg consumption and other dietary exposures. The endpoint was the rate of major cardiovascular events (myocardial infarction, stroke or death from cardiovascular causes). RESULTS: A major cardiovascular event occurred in 342 participants. Baseline egg consumption was not significantly associated with cardiovascular events in the total population. Non-diabetic participants who ate on average >4 eggs/week had a hazard ratio (HR) of 0.96 (95% confidence interval, 0.33-2.76) in the fully adjusted multivariable model when compared with non-diabetic participants who reported the lowest egg consumption (<2 eggs/week). Among diabetic participants, the HR was 1.33 (0.72-2.46). There was no evidence of interaction by diabetic status. HRs per 500 eggs of cumulative consumption during follow-up were 0.94 (0.66-1.33) in non-diabetics and 1.18 (0.90-1.55) in diabetics. CONCLUSIONS: Low to moderated egg consumption was not associated with an increased CVD risk in diabetic or non-diabetic individuals at high cardiovascular risk. This trial was registered at controlled-trials.com as ISRCTN35739639., Supported by the official funding agency for biomedical research of the Spanish Government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140, to RE; RTIC RD 06/0045, to Miguel A. Martínez-Gonzalez) and through Centro de Investigaci on Biomedica en Red de Fisiopatología de la Obesidad y Nutrici on (CIBERobn), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), the Fondo de Investigacion Sanitaria eFondo Europeo de Desarrollo Regional (Proyecto de Investigacion (PI) 04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/ 1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462), the Ministerio de Ciencia e Innovacion (Recursos y teconologia agroalimentarias (AGL)-2009-13906-C02 and AGL2010-22319-C03 and AGL2013-49083-C3-1-R), the Fundacion Mapfre 2010, the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, the Generalitat Valenciana (Generalitat Valenciana Ayuda Complementaria (GVACOMP) 06109, GVACOMP2010-181, GVACOMP2011-151), Conselleria de Sanitat y AP; Atencion Primaria (CS) 2010-AP-111, and CS2011-AP-042, and Regional Government of Navarra (P27/2011).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Red blood cell eicosapentaenoic acid inversely relates to MRI-assessed carotid plaque lipid core burden in elders at high cardiovascular risk

  • Bargallo, Nuria
  • Gilabert, Rosa
  • Romero-Mamani, Edwin-Saúl
  • Cofán, Montserrat
  • Calder, Philip C.
  • Fitó Colomer, Montserrat
  • Corella, Dolores
  • Salas-Salvadó, Jordi
  • Ruiz-Canela, Miguel
  • Estruch, Ramón
  • Ros, Emilio
  • Sala Vila, Aleix
Supplemental marine omega-3 eicosapentaenoic acid (EPA) has an anti-atherosclerotic effect. Clinical research on EPA supplied by the regular diet and atherosclerosis is scarce. In the framework of the PREvención con DIeta MEDiterránea (PREDIMED) trial, we conducted a cross-sectional study in 161 older individuals at high vascular risk grouped into different stages of carotid atherosclerosis severity, including those without ultrasound-detected atheroma plaque (n = 38), with plaques <2.0 mm thick (n = 65), and with plaques ≥2.0 mm (n = 79). The latter were asked to undergo contrast-enhanced 3T magnetic resonance imaging (MRI) and were subsequently grouped into absence (n = 31) or presence (n = 27) of MRI-detectable plaque lipid, a main feature of unstable atheroma plaques. We determined the red blood cell (RBC) proportion of EPA (a valid marker of long-term EPA intake) at enrolment by gas chromatography. In multivariate models, EPA related inversely to MRI-assessed plaque lipid volume, but not to maximum intima-media thickness of internal carotid artery, plaque burden, or MRI-assessed normalized wall index. The inverse association between EPA and plaque lipid content in patients with advanced atherosclerosis supports the notion that this fatty acid might improve cardiovascular health through stabilization of advanced atheroma plaques., CIBEROBN is an initiative of ISCIII, Spain. This study was funded in part by ISCIII (Spanish Ministry of Economy) through grants RTIC G03/140, RTIC RD 06/0045, Centro Nacional de Investigaciones Cardiovasculares CNIC 06/2007, ISCIII FIS PS09/01292; the Spanish Ministry of Science and Innovation (MICINN): AGL2010-22319-C03-02 and AGL2009-13906-C02-02; Fundació “La Marató de TV3”: 294/C/2015. AS-V holds a Miguel Servet I contract (CP12/03299, Instituto de Salud Carlos III, Spain). The funding sources had no involvement in the study design, data collection, analyses, and interpretation of the data or writing of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Association between dietary fibre intake and fruit, vegetable or whole-grain consumption and the risk of CVD: results from the PREvención con DIeta MEDiterránea (PREDIMED) trial

  • Buil-Cosiales, Pilar
  • Fitó Colomer, Montserrat
  • PREDIMED investigators
Prospective studies assessing the association between fibre intake or fibre-rich food consumption and the risk of CVD have often been limited by baseline assessment of diet. Thus far, no study has used yearly repeated measurements of dietary changes during follow-up. Moreover, previous studies included healthy and selected participants who did not represent subjects at high cardiovascular risk. We used yearly repeated measurements of diet to investigate the association between fibre intake and CVD in a Mediterranean cohort of elderly adults at high cardiovascular risk. We followed-up 7216 men (55-80 years) and women (60-80 years) initially free of CVD for up to 7 years in the PREvención con DIeta MEDiterránea study (registered as ISRCTN35739639). A 137-item validated FFQ was repeated yearly to assess diet. The primary end point, confirmed by a blinded ad hoc Event Adjudication Committee, was a composite of cardiovascular death, myocardial infarction and stroke. Time-dependent Cox's regression models were used to estimate the risk of CVD according to baseline dietary exposures and to their yearly updated changes. We found a significant inverse association for fibre (P for trend=0·020) and fruits (P for trend=0·024) in age-sex adjusted models, but the statistical significance was lost in fully adjusted models. However, we found a significant inverse association with CVD incidence for the sum of fruit and vegetable consumption. Participants who consumed in total nine or more servings/d of fruits plus vegetables had a hazard ratio 0·60 (95 % CI 0·40, 0·96) of CVD in comparison with those consuming <5 servings/d., The study was financially supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to G03/140, to RE; RTIC RD 06/0045, to MAM-G) and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), the Fondo de Investigación Sanitaria–Fondo Europeo de Desarrollo Regional (Proyecto de Investigación (PI) 04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/ 0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462), the Ministerio de Ciencia e Innovación (Recursos y teconologia agroalimentarias (AGL)-2009-13906-C02 and AGL2010-22319-C03 and AGL2013-49083-C3-1-R), the Fundación Mapfre 2010, the Consejería de Salud de la Junta de Andalucía (PI0105/2007), the Public Health Division of the Department of Health of the Autonomous Government of Catalonia, the Generalitat Valenciana (Generalitat Valenciana Ayuda Complementatia (GVACOMP) 06109, GVACOMP2010-181, GVACOMP2011-151), Conselleria de Sanitat y AP; Atención Primaria (CS) 2010-AP-111, and CS2011-AP-042) and Regional Government of Navarra (P27/2011).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Chromium Exposure and Risk of Cardiovascular Disease in High Cardiovascular Risk Subjects - Nested Case-Control Study in the Prevention With Mediterranean Diet (PREDIMED) Study

  • Gutiérrez Bedmar, Mario
  • Martínez-González, Miguel Ángel, 1957-
  • Muñoz-Bravo, Carlos
  • Ruiz-Canela, Miguel
  • Mariscal, Alberto
  • Salas Salvadó, Jordi
  • Estruch, Ramón
  • Corella, Dolores
  • Arós, Fernando
  • Fitó Colomer, Montserrat
  • Lapetra, José
  • Serra-Majem, Luis
  • Ros, Emilio
  • Alonso-Gómez, Ángel
  • Portolés, Olga
  • Fiol, Miquel
  • Bulló, Mònica
  • Castañer, Olga
  • Pinto, Xavier
  • Gómez-Gracia, Enrique
BACKGROUND: Epidemiological data on chromium (Cr) exposure and the risk of cardiovascular disease (CVD) are still limited. Toenail Cr level (TCL) provides a time-integrated measure reflecting long-term Cr exposure. We measured TCL to assess the hypothesis that long-term Cr exposure was inversely associated with incident CVD in a population at high risk for CVD.Methods and Results:The associations between TCL and CVD were evaluated in a case-control study nested within the "PREvención con DIeta MEDiterránea" (PREDIMED) trial. We randomly selected 147 of the 288 patients diagnosed with CVD during follow-up and matched them on age and sex to 271 controls. Instrumental neutron activation analysis was used to assess TCL. In-person interviews, medical record reviews, and validated questionnaires were used to assess covariates. The fully adjusted OR for the highest vs. lowest quartile of toenail Cr was 0.54 (95% CI: 0.26-1.14; Ptrend=0.189) for the nested case-control study. On stratification for diabetes mellitus (DM), OR was 1.37 (95% CI: 0.54-3.46; Ptrend=0.364) for the DM group, and 0.25 (95% CI: 0.08-0.80; Ptrend=0.030) for the non-DM group (P for interaction=0.078). CONCLUSIONS: The present findings, although not statistically significant, are consistent with previously reported inverse associations between TCL and CVD. These results, especially for non-DM patients, increase the limited epidemiological knowledge about the possible protective role of Cr against CVD. (Trial registration: www.controlled-trials.com; ISRCTN35739639.)., This research was supported by the official funding agency for biomedical research of the Spanish Government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140 to R.E.; RTIC RD 06/0045 “PREDIMED” to M.A.M-G.), and JR14/00008 to O.C., and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERobn), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (Proyecto de Investigación (PI) 04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505 and PI13/00462), Ministerio de Ciencia e Innovación (Recursos y teconologia agroalimentarias (AGL)-2009-13906-C02 and AGL2010-22319-C03 and AGL2013-49083C3-1-R), Fundación Mapfre 2010, Consejería de Salud de la Junta de Andalucía (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (Generalitat Valenciana Ayuda Complementatia GVACOMP) 06109, GVACOMP2010-181, GVACOMP2011-151), Conselleria de Sanitat y AP; Atención Primaria (CS) 2010-AP-111, and CS2011-AP-042), Regional Government of Navarra (P27/2011), and Centre Català de la Nutrició de l’Institut d’Estudis Catalans. Hojiblanca and Patrimonio Communal Olivarero donated extra-virgin olive oil; the California Walnut Commission donated walnuts; Borges donated almonds; La Morella Nuts donated hazelnuts.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Metabolites related to purine catabolism and risk of type 2 diabetes incidence, modifying effects of the TCF7L2-rs7903146 polymorphism

  • Papandreou, Christopher|||0000-0002-6803-507X
  • Li, Jun
  • Liang, Liming|||0000-0001-8261-3174
  • Bulló, Mònica|||0000-0002-0218-7046
  • Zheng, Yan
  • Ruiz-Canela, Miguel|||0000-0002-7684-2787
  • Yu, Edward
  • Guasch-Ferré, Marta
  • Razquín, Cristina|||0000-0003-3480-2645
  • Clish, Clary|||0000-0001-8259-9245
  • Corella, Dolores|||0000-0002-2366-4104
  • Estruch, Ramón|||0000-0003-1260-4445
  • Ros, Emilio|||0000-0002-2573-1294
  • Fitó, Montserrat|||0000-0002-1817-483X
  • Arós, Fernando
  • Serra-Majem, Luís|||0000-0002-9658-9061
  • Rosique, Nuria
  • Martínez-González, Miguel A.
  • Hu, Frank B..
  • Salas-Salvadó, Jordi|||0000-0003-2700-7459
Studies examining associations between purine metabolites and type 2 diabetes (T2D) are limited. We prospectively examined associations between plasma levels of purine metabolites with T2D risk and the modifying effects of transcription factor-7-like-2 (TCF7L2) rs7903146 polymorphism on these associations. This is a case-cohort design study within the PREDIMED study, with 251 incident T2D cases and a random sample of 694 participants (641 non-cases and 53 overlapping cases) without T2D at baseline (median follow-up: 3.8 years). Metabolites were semi-quantitatively profiled with LC-MS/MS. Cox regression analysis revealed that high plasma allantoin levels, including allantoin-to-uric acid ratio and high xanthine-to-hypoxanthine ratio were inversely and positively associated with T2D risk, respectively, independently of classical risk factors. Elevated plasma xanthine and inosine levels were associated with a higher T2D risk in homozygous carriers of the TCF7L2-rs7903146 T-allele. The potential mechanisms linking the aforementioned purine metabolites and T2D risk must be also further investigated.